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ABSTRACT 
Background: Loss of adipose and muscle tissue mass is a key feature of cancer cachexia. Weight loss, 
glucose intolerance, and insulin resistance are seen in patients with pancreatic ductal adenocarcinoma 
(PDAC). The mechanism behind the loss of adipose tissue is unknown but has been attributed to 
increased adipocyte lipolysis, systemic inflammation, apoptosis or reduced lipogenesis. The volume of 
adipose and muscle tissue in cancer cachexia can be determined by computed tomography (CT).  
Aims: The aim of this research was to: 1) Investigate the action of insulin on glucose metabolism and the 
content of energy metabolites in the muscle tissue of patients with PDAC.  2) Determine whether 
alterations in fat cell numbers, lipolysis and lipogenesis could account for some of the functional 
changes observed in adipose tissue in cancer cachexia. 3) Investigate if inflammation is involved in the 
loss of adipose tissue in cancer cachexia. 4) CT determined tissue volume, could give information about 
the distribution of wasting of muscle and adipose tissue in patients with recently diagnosed cancer 
cachexia.  
Material and Methods: Muscle biopsies from patients with PDAC and three control groups were 
assessed for glycogen, adenosine triphosphate and phosphocreatine content. Also measured were 
glucose incorporation into glycogen, glucose transport in human muscle and rat muscle cell conditioned 
by PDAC cells. In cancer cachexia patients (CC) and two cancer control patient groups, weight stable 
(WS,) and gastric obstruction (GO), blood, subcutaneous adipocytes and differentiated preadipocytes 
were investigated for: 1) Expression of genes regulating inflammation and measurement of systemic 
and local secretion of inflammation markers (interleukin 6 (IL-6)). 2) In vivo lipolytic activity, lipolysis, 
lipogenesis and expression of genes regulating lipolysis. 3) Measurements of number and volume of 
adipocytes. The volume of muscle and adipose tissue was measured with CT and body composition. 
Results: Patients in the CC group lost 10% of their habitual weight, patients in GO group lost 17% and 
patients in WS group lost 3%. Glucose transport, muscle glycogen, and adenosine triphosphate contents 
were decreased in patients with PDAC compared with control patients, and insulin stimulation did not 
significantly increase glucose incorporation into glycogen in vitro in patients with PDAC. Media 
conditioned with PDAC cells did not affect glucose transport in rat muscle cell. Circulating levels of IL-6 
and in vivo lipolytic activity were increased in patients in the CC group compared to control patients. In 
patients in the CC group, there was increased lipolytic effect of catecholamines and natriuretic peptide, 
and the expression levels of Hormone Sensitive Lipase (HSL) mRNA and protein were increased 
compared to those in the control patients. The antilipolytic effect of insulin in mature adipocytes and 
the stimulated lipolytic effect in differentiated preadipocytes were unaltered in cancer cachexia. 
Patients in the GO group had no change in adipocyte lipolysis. There were no differences in mRNA 
expression of IL-6 or secretion in adipose tissue and lipogenesis. Adipocytes were decreased in size but 
their numbers were normal in patients in the CC group compared with those in the WS control group. 
Adipose tissue was reduced in patients in the CC and GO groups, both according to CT and body 
composition. CT showed that patients in the CC group displayed a selective decrease in visceral adipose 
tissue. 
Conclusion: Wasting of adipose tissue is a prominent part of the cancer cachexia syndrome and 
commences before the wasting of muscle tissue. The insulin resistance for active glucose transport in 
the skeletal muscle of pancreatic cancer patients is not directly related to factors from pancreatic 
cancer. It is lipolysis, not inflammation, increased apoptosis or decreased lipogenesis, which is involved 
in the loss of adipose tissue in patients with cancer cachexia. There is increased expression and activity 
of HSL, which gives rise to an increased rate of lipolysis in patients with cancer cachexia. Although 
cancer patients with gastrointestinal obstruction, at the time of diagnosis, have lost almost twice the 
amount of body weight compared to patients with cancer cachexia, the latter group displays more loss 
of visceral adipose tissue. 
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1 INTRODUCTION 
 
1.1 GENERAL INTRODUCTION 
The word cachexia, made from the words kakos and hexis, originates from the Greek 
language and is a description of a bad condition. 
 
The idea that a tumour substance can give rise to cancer cachexia was published for the 
first time in 1962.  Before that time it was believed that the body destroyed fat and 
muscle tissue in order to ―feed‖ the tumour [1]. 
   
For decades has it been difficult to define the cachexia syndrome. In advanced 
cachexia, though not in early, the most dramatic symptoms are weight loss and 
anorexia, as well as early satiety, anaemia, and oedema [2]. In the early stages of 
cachexia, these features may occur to a variable degree but the severity of symptoms 
may change during the course of the illness. The complex, multifactorial origin of 
cachexia does not follow a uniform pathophysiological profile and this has created 
obstacles to conducting clinical studies both at a mechanical level and in order to target 
therapeutic interventions [2]. The cancer cachexia syndrome is common in patients 
with gastrointestinal cancer [3, 4]. In these patients cancer cachexia is a collective term 
for all the signs and symptoms they may develop, which are not related to or caused by 
the mechanical compression or obstruction of the cancer or by the treatment of the 
cancer such as chemotherapy, radiotherapy or surgery [5]. Cachexia induced by the 
treatment of the cancer is likely to be caused by  different pathophysiological 
mechanisms from those resulting in cancer cachexia [5], as the body composition 
following anorexia induced weight loss is more  similar to what is  observed in 
starvation than in cancer cachexia [2]. The cancer cachexia syndrome includes weight 
loss, loss of muscle and adipose tissue, anaemia and alterations in lipid, protein and 
carbohydrate metabolism [6]. The loss of muscle and adipose tissue may precede any 
reduction in food intake, which can be normal or even increased [1, 7], however 
anorexia is commonly present in patients with cancer cachexia [7]. Non muscle protein 
compartments are relatively preserved in cancer cachexia, thus distinguishing cancer 
cachexia from simple starvation [2]. Even with intensive nutritional support, including 
total parenteral nutrition, it is difficult to reverse the process [8]. Although several 
theories regarding the pathophysiological mechanisms have been proposed there is no 
universally accepted explanation for the cause of cancer cachexia [9-11]. Cancer 
patients with cachexia, have shorter median survival, more psychological problem and 
worse quality of life than cancer patients without cachexia [12]. Loss of respiratory 
muscle in cancer cachexia patients has been found to contribute to up to 50% of deaths 
in cancer patients [13]. Weight loss approaching 30% is incompatible with life [2]. 
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1.2 DEFINITIONS 
1.2.1 Cachexia 
1.2.1.1 General 
Until 2006 there was no official definition of cachexia. Due to there being many 
different types of cachexia it is very important when discussing cachexia to know what 
definition is being used. For example today’s treatment of patients with heart-, lung- 
and renal failure is so advanced that it has converted groups of dying patients to living 
patients left with chronic diseases. All these patients, along with patients suffering from 
chronic infections (tuberculosis or HIV), rheumatic disease and cancer, can develop a 
condition called cachexia. To make this more complicated, since 2006, several different 
definitions of cachexia have been published.  
 
Three of these definitions are: 
1. European Palliative Care Research Collaborative organization: „„Cancer 
cachexia is a multifactorial syndrome defined by a negative protein and energy 
balance driven by a variable combination of reduced food intake and abnormal 
metabolism. A key defining feature is ongoing loss of skeletal muscle mass 
which cannot be fully reversed by conventional nutritional support, leading to 
progressive functional impairment‟‟ [14].  
 
2. Special Interest Group on Cachexia and Anorexia:  
„„Cachexia is a multifactorial syndrome characterized by severe body weight 
loss, muscle and fat loss and increased protein catabolism due to underlying 
disease(s). Cachexia is clinically relevant since it increases patients‟ morbidity 
and mortality. Contributory factors to the onset of cachexia are anorexia and 
metabolic alterations, i.e., increased inflammatory status, increased muscle 
proteolysis, impaired carbohydrate, protein and lipid metabolism. Considering 
the wide range of clinical manifestations of cachexia, the staging of this 
syndrome is warranted‟‟ [15]. 
 
3. Society for Cachexia and Wasting Disorders:  
„„Cachexia is a complex metabolic syndrome associated with underlying illness 
and characterized by loss of muscle with or without loss of fat mass. The 
prominent clinical feature of cachexia is weight loss in adults (corrected for 
fluid retention) or growth failure in children (excluding endocrine disorders). 
Anorexia, inflammation, insulin resistance and increased muscle protein 
breakdown are frequently associated with wasting disease. Wasting disease is 
distinct from starvation, age-related loss of muscle mass, primary depression, 
malabsorption and hyperthyroidism and is associated with increased 
morbidity” [16]. 
 
 
At the 5
th
 Cachexia Conference, in Barcelona Spain, December 2009, a consensus was 
reached between representatives of these three groups. All three different definitions 
were accepted and it was decided that they are in the most part alike [17]. In table 1 the 
three definitions are compared.       
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Table 1. Terms included in the different definitions (J Am Med Dir Assoc, 2010, vol. 10, Page 229-30). 
Condition 
European Palliative Care 
Research Collaborative 
organization 
Special Interest 
Group on Cachexia 
and Anorexia 
Society for Cachexia 
and Wasting Disorders 
Weight loss + + + 
Muscle loss + + + 
Fat loss - + -/+ 
Anorexia + + + 
Inflammation -/+ + + 
Insulin resistance - + + 
Muscle protein 
breakdown 
- + + 
Fatigue - - + 
Morbidity + + + 
Sarcopenia + + + 
Starvation - - + 
Reversion by nutritional 
support 
+ - - 
 
During this conference the need to work on more disease-specific definitions was 
pointed out and also the necessity to include the term ―pre-cachexia‖ as a condition 
with no or very small weight loss (< 5% of habitual body weight in 6 months). Pre-
cachexia is a condition that is associated with chronic disease in conjunction with 
anorexia, inflammation and/or metabolic alterations [17]. 
 
1.2.1.2 Related to the thesis 
When preparations were commenced in 2003 for the research leading to the published 
studies included in this thesis, including recruitment of the first patients in the spring of 
2004, there was no definition for cachexia or cancer cachexia available. The following 
definition was therefore constructed. 
 
CANCER CACHEXIA: 
Unintentional weight loss with no evidence of gastrointestinal 
obstruction, with > 5% of habitual weight lost during the last three 
months or > 10% weight loss during the last six months.  
 
This definition was based on findings from a literature search regarding what is 
considered to be normal weight loss over a given period of time. The finding from this 
literature search was that any weight loss of > 5% of habitual weight during a period of 
six months [18] was abnormal.  However a more constricted definition was used in this 
research to minimise the risk of false positive diagnosis of cancer cachexia. 
Consequently there was an increased risk of false negative results in weight stable 
cancer patients. It was decided that this was acceptable because there would be few 
patients included in the study, and the outcome should have such magnitude (true 
positive), that borderline changes (false negative) would not be relevant.  
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The definition of cancer cachexia used in this thesis is based on weight loss only. 
According to more recent definitions [14-16] of cachexia and cancer cachexia, weight 
loss alone is not sufficient to diagnose cachexia. Most of the other parameters required 
are parameters that were investigated in this thesis.  
 
1.2.2 Anorexia 
The definition of Anorexia is the loss of the desire to eat. It should not be confused with 
Anorexia Nervosa [15], a psychiatric disease, which is much less common than 
anorexia but more widely publicised in the media. Multifactorial pathology lies behind 
anorexia and may be related to a disturbance in the function of the hypothalamus, 
where energy intake is controlled.  Hypotheses exist that chronic systemic 
inflammation alters the function of the hypothalamus, resulting in a change in its 
function that renders the hypothalamus unable to recognize and respond appropriately 
to persistent peripheral hunger signals [19]. Anorexia is often associated with cancer 
cachexia but not always; there are cancer cachexia patients who show no signs of 
anorexia [5]. 
 
1.2.3 Sarcopeni  
Sarcopeni, made from the words sarx and penia, comes from the Greek language and 
describes the poverty of flesh. The term sarcopenia is commonly used to describe the 
loss of skeletal muscle mass and strength that occurs as part of the normal aging 
process. By the seventh and eighth decade of life, maximum voluntary contractile 
strength has decreased by 20-40% [20]. Most of the loss of strength can be accounted 
for by decreased muscle mass [21]. Loss of skeletal muscle fibres secondary to 
decreased numbers of motor-neurons appears to be a major contributing factor, but 
other factors, including decreased physical activity, altered hormonal status, decreased 
total caloric and protein intake, inflammatory mediators and factors leading to altered 
protein synthesis must also be considered [15, 22]. 
 
1.3 WHO GETS CANCER CACHEXIA? 
The typical cancer cachexia patient is a patient with pancreatic ductal adenocarcinoma 
(PDAC). These patients have the highest chances of all cancer patients of developing 
cancer cachexia with 85% of them becoming cachectic. It is not known why a few 
pancreatic cancer patients do not develop cancer cachexia but it is believed that this is 
due to variations in the tumour phenotype, or the host genotype or both, and that these 
factors determine the development of cancer cachexia [5]. Cancer cachexia is common 
in all patients with gastrointestinal cancer, while patients with non-Hodgkin's 
lymphoma, breast cancer, acute lymphocytic leukaemia, and sarcomas have the lowest 
frequency of cancer cachexia [5]. 
 
1.4 SIGNS AND SYMPTOMS OF CANCER CACHEXIA 
1.4.1 Weight Loss  
1.4.1.1 Adipose Tissue 
Wasting of adipose tissue occurs early in cancer cachexia [23]. Loss of adipose tissue 
stores cannot be explained by reduced appetite alone, as cancer cachexia often precedes 
the onset of anorexia. Weight loss is more severe in animal models of cachexia than of 
   13 
food restriction [24]. Increased plasma glycerol levels [25] indicate increased lipolysis 
activity in cancer cachexia. Increased production of lipolytic factors from adipose tissue 
such as interleukin 6 (IL-6) and tumour necrosis factor alpha (TNF-α) and an increase 
in tumour-derived lipolytic factors such as Zinc-α-2-glycoprotein (ZAG) could explain 
the increased lipolysis in cancer cachexia [26, 27]. Altered action of the major lipolysis-
regulating hormones may additionally be of importance [26]. These hormones regulate 
lipolysis by separate mechanisms, all of which converge at the final rate-limiting step in 
lipolysis activation, with activation of hormone-sensitive lipase (HSL) [28]. 
Subcutaneous adipose tissue in cancer cachexia is characterised by atrophy and 
reduction in adipocyte cell size, and is accompanied by an increase in tissue matrix 
fibrosis [29].  
 
1.4.1.1.1 Adipocyte Lipase Activity 
In basal (not stimulated) lipolysis, adipose triglyceride lipase (ATGL) is more active 
than HSL. Both ATGL (highly active) and HSL (minimally active) hydrolyse 
triglycerides to diacylglycerol. In basal lipolysis (minimal HSL activity), diacylglycerol 
is re-esterified back to triglycerides or is used to build glycerolphospholipids. But when 
HSL is stimulated (via catecholamine or natriuretic peptides) HSL hydrolyses 
diacylglycerol to monoacylglycerol and monoglyceride lipase hydrolyses 
monoglyceride to glycerol. When HSL is extremely active or over-expressed, 
adipocytes cannot accumulate triglycerides [30, 31]. 
 
1.4.1.2 Muscle Tissue 
Wasting of muscle tissue in cancer cachexia occurs later than the wasting of adipose 
tissue [23]. Most studies in cancer patients with a weight loss of 10% or more have 
suggested an increased activity and expression of the ubiquitin-proteasome pathway in 
skeletal muscle [32] resulting in breakdown of the muscle. It has been suggested that 
depression of protein synthesis may be more important when the weight loss increases 
to more than 20%. The mechanism for the muscle wasting at weight losses greater than 
20% requires further investigation, the ubiquitin-proteasome pathway alone cannot 
account for the high levels of protein breakdown observed [33]. 
  
1.4.2 Body Composition 
It is important to realize that the changes in body composition reflect a process that 
changes with time. In a group of cancer patients who had lost 10% of their habitual 
weight, adipose tissue diminished preferentially from the chest and abdomen, 
followed by leg and arm adipose tissue, respectively. Lean body mass diminished 
from the arm tissue compartment, whereas in the central body areas and leg tissue 
compartments it increased [23]. In another group of cancer patients who had lost 30% 
of their habitual weight, an 85% decrease in total body adipose tissue and a 75% 
decrease in skeletal muscle protein mass were the most dramatic changes observed in 
body composition. Interestingly, the visceral protein compartment was relatively 
preserved and this is one of the main features that differentiates cancer cachexia from 
simple starvation [2]. The body composition alterations in cancer cachexia differ from 
that seen in anorexia, where most of the weight loss is from adipose tissue, and only a 
small proportion from muscle, whereas in cancer cachexia there is an equal loss of 
adipose and muscle tissue (late stages of cancer cachexia). Additionally in Anorexia 
Nervosa, the loss of visceral (non muscle) protein mass occurs in proportion to the 
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loss of muscle mass, while in cancer cachexia visceral protein mass is conserved, and 
may even increase [5]. 
 
1.4.3 Energy Expenditure  
Increased energy expenditure may contribute to the wasting process seen in cancer 
cachexia. About 70% of the total energy expenditure in healthy individuals at rest arises 
from the resting energy expenditure (REE). The REE in cancer patients is strongly 
determined by the type of tumour present. REE has been found to be elevated in 
patients with both lung [34] and pancreatic cancer [35], whereas no increase in REE is 
found in patients with gastric and colorectal cancer [34]. These observations may 
however depend on where in the cancer cachexia process the patient is, newly 
diagnosed or near death [5]. 
 
1.4.4 Acute Phase Response  
In patients with pancreatic cancer, REE is significantly higher in those patients who 
demonstrate an elevated acute phase response (APR) [35]. The APR constitutes a series 
of changes in liver protein synthesis, with a shift from production of albumin to acute 
phase proteins (APP), such as CRP, fibrinogen, serum amyloid A, 2-macroglobulin, 
and α-1 antitrypsin. These changes are also observed as a response to tissue injury, 
infection, or inflammation [5]. 
 
1.4.5 Systemic Inflammation 
Animal studies initially suggested that there was a role for pro-inflammatory cytokines 
in cancer cachexia. IL-1, IL-6, TNF-α and IFN-γ are associated with anorexia and 
weight loss in rodent tumour models [36-38]. These pro-inflammatory cytokines are 
inducers of the APR. In cancer patients the circulating concentration of IL-6 correlates 
well with markers of systemic inflammation such as C-Reactive Protein (CRP) [37]. 
CRP is the prototypical positive acute phase response and is measured routinely in the 
clinical setting. The presence of such an acute phase reaction can then be interpreted as 
an indirect marker of pro-inflammatory cytokine activity (IL-1, IL-6 and TNF-α), and 
serum CRP concentration has been positively correlated with weight loss [39, 40]. REE 
in patients with pancreatic cancer is increased compared with controls, and those 
patients demonstrating an APR have a higher REE when compared with cancer patients 
without Acute Phase Response [35]. This explains why inflammation is associated with 
cancer cachexia [37]. Long exposure to inflammatory agents in adipose tissue increases 
lipolysis [41]. 
 
1.4.6 Glucose Intolerance 
Skeletal muscle and adipose tissue are important factors in maintaining normal glucose 
concentrations, and this is regulated by insulin. Glucose intolerance occurs in the 
majority of patients with pancreatic cancer [42] and is the result of increased peripheral 
insulin resistance [43]. This peripheral insulin resistance is partially relieved after the 
pancreatic tumour is removed [44]. Insulin resistance in cancer cachexia is associated 
with increased expression of mRNA for TNF-α and reduced mRNA expression of 
GLUT4, an active insulin dependent glucose transporter. TNF-α reduces insulin 
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signalling by inhibiting both tyrosine kinase activity at the insulin receptor site and 
reducing phosphatidylinositol-3-kinase activity [38]. 
 
 
1.5 TREATMENT OF CANCER CACHEXIA 
There is no optimum treatment available for cancer cachexia and treatment until now 
has been focused on treating the signs and symptoms. Presently however the treatments 
that are being designed are attempting to target the pathophysiological pathways that 
cause cancer cachexia as these become better understood. The mainstay of present 
treatment is dietary consultation and emotional support [16]. All other forms of 
treatment are still experimental and should only be used in clinical trials.  
 
1.5.1 Total Parenteral Nutrition  
There is no role for total parenteral nutrition in catabolic patients with cancer cachexia. 
These patients are not starving and they have normal gastrointestinal function. All 
measures should be taken to support targeted food quantity and quality. In this clinical 
situation the supply of additional calories is not effective and only causes side effects 
[16]. Questions have now been raised about the above statement regarding the 
ineffectiveness of total parenteral nutrition as an addition to chemo- or radiotherapy in 
patients with cancer cachexia. There is a lack of up to date research in this field [16]. 
TPN is a life-saving method of nutritional support in patients who have gastrointestinal 
obstruction, pain or other ―mechanical reason‖ for being unable to eat [45, 46]. 
  
1.5.2 Agents Affecting Appetite 
1.5.2.1 Ghrelin receptor agonist 
Ghrelin is produced in the upper part of the stomach and has a potent stimulating effect 
on stomach motility. It is released from the gastric mucosa in the upper part of the 
stomach, as a response to starvation and thereby stimulates food intake [47, 48]. It is 
additionally a potent stimulator of appetite and is used in clinical trials for the treatment 
of post-operative ileus and diabetic gastro pares. In a study of 60 cancer cachexia 
patients, ghrelin administration increased muscle strength and lean body mass but had 
no effect on body weight or the quality of life.  The disadvantages are that ghrelin has 
to be administered as a continuous intravenous infusion [5, 38]. 
 
1.5.2.2 Corticosteroids  
Because of their catabolic effect on skeletal muscle [49], corticosteroids such as 
dexamethasone, prednisolone, and methylprednisolone are used clinically to enhance 
appetite, the sensation of well-being and of performance, usually at the end-stages of 
cancer. Despite improvements observed in the quality of life, they have however, no 
beneficial effect on body weight [5, 16]. 
 
1.5.2.3 Megestrol Acetate 
Megestrol Acetate is a synthetic progestin, that stimulates appetite through the 
hypothalamus [50] and/or by down regulating the synthesis and release of pro-
inflammatory cytokines[51]. Following its administration an increase in appetite, 
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quality of life and body weight is observed. Analysis of body composition shows that 
there is an increase in adipose tissue mass but not in lean body mass [52].  Side effects 
include an increased risk of thromboembolism, an increase in oedema, reduced 
response to chemotherapy and a shorter survival trend is observed [5, 16, 38].  
 
1.5.2.4 Cannabinoids  
Cannabinoids stimulate appetite and mood and increase the quality of life but do not 
increase body weight. The negative effect seen on gastrointestinal motility can cause 
problems and outweigh its benefits [5, 16, 38].   
 
1.5.3 Agents Affecting Mediators or Signalling Pathways  
1.5.3.1 Anabolic steroids 
Anabolic agents, such as the oral agent oxandrolone, are associated with an increase in 
body weight and lean body mass, improved nitrogen balance and quality of life in 
cachexia associated with infectious [53] or pulmonary diseases. Ongoing studies are 
currently investigating its role in the treatment of cancer cachexia [38, 54].  
 
1.5.3.2 ACE inhibitor 
Renin from the kidneys converts Angiotensin I to Angiotensin II. Angiotensin II is a 
potent arteriolar constrictor and increases blood pressure. Angiotensin II induces 
muscle catabolism, promotes anorexia and insulin resistance, and increases tumour 
angiogenesis [55]. In theory, Angiotensin II (ACE) inhibitors could protect against 
cancer cachexia. Published studies have shown some positive results and a phase III 
study is under way with results expected late in 2011 [38].    
  
1.5.3.3 Eicosapentaenoic acid (EPA)  
EPA is found in fish oil and it inhibits the expression and activity of the ubiquitin-
proteasome pathway and blocks NF-kβ activation. EPA reverses muscle atrophy and 
stimulates appetite, but to a much lesser extent than megestrol acetate. A combination 
of EPA and megestrol acetate does not have greater effect in stimulating appetite than 
megestrol acetate alone [56]. It requires to be investigated if this combination of 
therapy has fewer side effects than using megestrol acetate alone. EPA preserves 
adipose tissue [57] and this may be due to the down regulating effects on ZAG [5, 57].  
 
1.5.3.4 β-Hydroxy-β-Methylbutyrate (HMB) 
HMB is similar to EPA, inhibits the expression and activity of the ubiquitin-proteasome 
pathway [58] and blocks NF-kβ activation. In advanced cancer cachexia, treatment with 
HMB increases body weight and lean body mass, with no changes in adipose tissue 
mass [59].  
    
1.5.3.5 Megestrol Acetate 
There is evidence available that progestin can inhibit tumour growth by interference in 
the G1 phase of cell division (unknown mechanism) [60].   
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1.5.3.6 Thalidomide 
Thalidomide has various actions including the inhibition of TNF-α production, 
angiogenesis, down regulation of the ubiquitin-proteasome pathway and it blocks NF-
kβ activation [61]. It delays the loss of body weight and lean body mass in cancer 
cachexia [62], but does not increase the quality of life. Side effects include increased 
risk of thromboembolism, neuropathy and it has a negative effect on gastrointestinal 
motility. The severity of the side effects, with only relatively minor positive treatment 
success, gives it a limited therapeutic potential in cancer cachexia [5, 38, 63]. 
 
1.5.3.7 Nonsteroidal Anti-Inflammatory Agents (NSAIDs) 
NSAIDs alone or in combination with megestrol acetate, reduce REE and serum CRP, 
increase body weight, improve the quality of life and prolong mean survival time in 
patients with cancer cachexia [64].   
 
1.5.4 Surgery 
There are no prospective studies available involving patients who have well defined 
cancer cachexia before surgical operation and appropriate confirmation of cancer 
cachexia by assessment of body composition performed pre and post-operatively. There 
are published studies on pancreatic cancer patients showing that peripheral insulin 
resistance is partially relieved post-operatively [44]. Patients with cancer cachexia have 
a mean survival of 451 days after operation  as compared to weight stable patients who 
have a mean survival of 654 days (p = 0,001) [65]. 
 
 
1.6 INTRODUCTION RELATED TO THE THESIS 
The presence of insulin resistance in skeletal muscle has been suggested in experiments 
on patients with PDAC [43, 66-68]. In addition, impaired insulin action on 
phosphatidylinositol-3-kinase activity, glucose transport, and glycogen synthesis 
activity has been shown [68, 69]. Insulin function is known to be dependent on the 
energy levels of the target cells [70]. Insulin-stimulated glucose transport into muscle 
cells and glucose non-oxidative metabolism to glycogen are energy-requiring processes 
that are impaired in patients with PDAC [68, 69]. This could imply that skeletal muscle 
insulin resistance in these patients is associated with a decreased muscle content of 
energy metabolites. Insulin resistance and weight loss are coupled to increased energy 
expenditure in patients with PDAC [35]. Decreased insulin action on skeletal muscle 
glucose transport and further metabolism of glucose into glycogen could therefore be 
influenced by a decreased muscle content of adenosine triphosphate (ATP) and 
phosphocreatine. PDAC cells could influence active glucose transport in skeletal 
muscle.  
Several studies regarding the relationship between body fat distribution and lipid 
metabolism show that visceral adipose tissue plays an important role in the 
pathophysiological alterations in lipid metabolism and insulin sensitivity [35, 69, 71]. 
Through elevated lipolysis, visceral adipose tissue releases increased levels of free fatty 
acids to the liver through the portal vein. Increased intrahepatic lipid concentration 
disturbs and deteriorates glucose and insulin homeostasis leading to peripheral insulin 
resistance [72].  
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Fig. 1. Flowchart showing the possible 
pathways involved in wasting of adipose 
tissue. 
 
Figure 1 shows an overview of possible 
pathways which could lead to wasting of 
adipose tissue and increased plasma level of 
free fatty acids. Increased production of 
lipolytic factors from adipose tissue such as 
IL-6 and TNF-α or tumour-derived lipolytic 
factors such as ZAG could explain the 
increased lipolysis in cancer cachexia [26, 
27]. Furthermore, altered action of the 
major lipolysis-regulating hormones, 
catecholamines (stimulatory), natriuretic 
peptides (stimulatory), and insulin 
(inhibitory), may be of importance [26]. 
These hormones regulate lipolysis by 
separate mechanisms, all of which converge at the final rate-limiting step in lipolysis 
activation i.e. hormone-sensitive lipase (HSL)) [28]. The recently described natriuretic 
peptide system is mediated by the cyclic guanosine 3,5-monophosphate (cGMP) 
pathway, which stimulates protein kinase G activating HSL [73]. Hormonal regulation 
of lipolysis in adipose tissue cells by insulin, catecholamines, and natriuretic peptides 
may be altered in cancer cachexia.  
White adipose tissue is a highly active tissue that, apart from its metabolic function, 
releases an array of secreted products that have both local and systemic effects on lipid 
and glucose metabolism [74]. Increased adipose tissue inflammation is an important 
factor in the development of obesity-related complications, such as insulin resistance 
[75, 76]. The infiltration of inflammatory cells, primarily macrophages, into the adipose 
tissue promotes local production of inflammatory mediators, such as cytokines, both 
from leukocytes and adipocytes, which in turn initiate a negative set of effects on 
adipocyte function [77] and insulin responsiveness and this may induce adipose tissue 
cell death. For instance, it is well established that IL-6 and TNF-α promote adipocyte 
lipolysis and attenuate insulin signalling through several mechanisms [78]. Furthermore 
TNF-α can induce apoptosis in human adipocytes [79]. Metabolic alterations, including 
increased insulin resistance, are observed when adipose tissue mass is reduced 
considerably [80]. The remaining adipose tissue in patients with cancer cachexia may 
display an altered inflammatory reaction that could promote significant changes in 
adipose tissue cell function, including increased lipolysis and possibly reduced 
lipogenesis. 
The volume of muscle and adipose tissue mass can be determined by computed 
tomography (CT). This is often assessed in clinical weight reduction trials in obese 
subjects with or without diabetes [81, 82]. The impact of cancer cachexia on the 
volume of muscle, subcutaneous and visceral adipose tissue in patients with recently 
diagnosed gastrointestinal cancer, is an interesting subject to consider investigating. 
Volume determined by CT could give information about distribution or wasting of 
muscle, subcutaneous and visceral adipose tissue in patients with recently diagnosed 
cancer cachexia [83]. 
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2 AIMS 
 
 
2.1 STUDY I 
To investigate if in pancreatic cancer: 
 
 Decreased insulin action on skeletal muscle glucose transport is 
influenced by decreased ATP levels in muscle cells 
 Pancreatic cancer cells change glucose metabolism in muscle       
 
2.2 STUDY II 
To investigate in cancer cachexia patients: 
 
 The rate of lipolysis  
 The factors involved in lipolysis  
 
 
2.3 STUDY III 
To investigate if in cancer cachexia patients: 
 
 Lipogenesis in adipose tissue is decreased 
 Inflammation in adipose tissue is increased 
 Apoptosis in adipose tissue is increased 
     
 
2.4 STUDY IV 
To investigate if in cancer cachexia patients: 
 
 There is a difference in the volume of adipose- and muscle 
compartments between cancer cachexia patients and benign 
disease control patients 
 Adipose tissue wasting is an early phenomenon in the cancer 
cachexia syndrome 
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3 MATERIALS AND METHODS 
 
3.1 STUDIES DESIGN 
In Study I, there were four groups of patients: 
a) Pancreatic Ductal Adenocarcinoma (PDAC) 
b) Other Cancers  
c) Chronic Pancreatitis (CP) 
d) Benign Controls 
 
The study patients were recruited consecutively at the surgical outpatient clinic or from 
those who were already scheduled for surgical treatment. Patients with known diabetes 
were excluded. Postoperatively, the correct diagnosis was confirmed in all patients by 
histopathological examination.  
 
In studies II-IV, patients with newly diagnosed gastrointestinal cancer who attended the 
surgical outpatient clinic between January 2004 and December 2008 were evaluated for 
inclusion in the study. Patients who had not received previous cancer treatment, and 
who were willing to participate, were included.  
 
Based on clinical examination by the same surgeon, patients were allocated to:  
 
a) Cancer cachexia group (CC):  Defined as those patients with unintentional 
weight loss of > 5% of habitual weight during the last three months or > 10% 
during the last six months and with no evidence of gastrointestinal obstruction 
 
b) Weight stable group (WS): Defined as those patients with unintentional weight 
loss of < 5% of habitual weight during the last three months and < 10% during 
the last six months and with no evidence of gastrointestinal obstruction 
 
c) Gastric obstruction (GO) group: Defined as those patients who reported weight 
loss as defined for the CC group above, in combination with evidence of 
obstructive gastrointestinal cancer, resulting in malnutrition. 
 
The researchers responsible for lipolysis and lipogenesis studies, gene and protein 
expression and secretions studies, preadipocyte and radiological studies were blinded 
regarding which groups the patients were in. Tumour staging was based on 
histopathological examination in those patients who had surgery and on a combination 
of radiological findings and case notes review in those patients who did not have 
surgery [84]. None of the patients had jaundice.  
 
The patients in studies II and IV were divided into three groups: 
a) Cancer cachexia 
b) Weight stable  
c) Gastric obstruction 
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Fig. 2. Flowchart for study I Patient’s examinations and muscle biopsy research. 
 
Fig. 3. Flowchart for study II, Patient’s examinations and adipose tissue biopsy research. 
 
The patients in study III were divided into three groups: 
a) Cancer cachexia 
b) Weight stable 
c) Patients with benign disease 
 
 
3.1.1 Study I 
The patients were divided into four groups: PDAC, other cancers, CP and benign 
controls. Venous blood samples were taken 
at the patient clinical laboratory and OGTT 
performed. Muscle biopsies were taken in 
the operating theatre and were frozen 
immediately or transported fresh directly to 
the research laboratory and analyzed for 
glycogen, adenosine triphosphate and 
phosphocreatine content. Glucose transport 
was monitored in muscle strips and 
myotubes (Fig. 2). 
    
 
 
  
3.1.2 Study II 
The patients were divided into three groups: 
cancer cachexia, weight stable and gastric 
obstruction. Adipose tissue biopsies were 
obtained under local anaesthesia, blood 
samples were taken and energy expenditure 
and body composition measured at the 
patient clinical laboratory. Adipose tissue 
biopsies were transported fresh to the 
research laboratory for measurement of 
lipolysis, protein and gene expression, and 
isolation of preadipocytes (Fig. 3). 
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Fig. 4. Flowchart for study III, Patient’s 
examinations and adipose tissue biopsy 
research. 
 
Fig. 5. Flowchart for study IV, Patient’s 
examinations and adipose tissue biopsy 
research. 
 
 
3.1.3 Study III  
The patients were divided into three groups, 
cancer cachexia, weight stable and no cancer. 
The no cancer group consisted of patients 
who were thought, before surgery, to have 
cancer, but who, after histopathological 
examination, were found not to have cancer. 
These patients were then reclassified. 
Adipose tissue biopsies were obtained under 
local anaesthesia and blood samples were 
taken at the patient clinical laboratory. 
Adipose tissue biopsies were transported 
fresh to the research laboratory for isolation 
of adipocytes and measurements of their 
weight, volume and number. Lipogenesis, 
gene expression and cytokine secretion was 
measured (Fig. 4).    
 
3.1.4 Study IV 
The patients were divided into three groups, 
cancer cachexia, weight stable and gastric 
obstruction. Blood samples were taken and 
energy expenditure and body composition 
measured at the patient clinical laboratory. 
Adipose and muscle tissue volume was 
measured with computed tomography (CT) 
(Fig. 5). Patients with benign disease, based 
on post-operative reclassification according 
to histopathological examination, were 
excluded.   
 
 
3.2 HUMAN CLINICAL STUDIES 
3.2.1 Clinical Examination 
In Study I, body weight was measured at the surgical outpatient clinic and OGTT was 
performed following an overnight fast. In studies II-IV, the patients attended the patient 
clinical laboratory after an overnight fast. Height, weight, hip and waist measurements 
were taken and body composition determined, with bioimpedance using Bodystat Quad 
Scand 4000 (Bodystat Ltd.). Basal Metabolic Rate (BMR) was calculated with a well-
established formula [85] and Energy Expenditure (EE) was measured by indirect 
calometry. The nutritional status was assessed by using a standardized questionnaire for 
oncology; patient-generated-subjective global assessment (PG-SGA) [86]. 
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3.2.2 Adipose Tissue Biopsies 
Abdominal subcutaneous WAT samples (0.5–1.5 g) were obtained by needle biopsy as 
described by others [87]. The tissue samples (≈5 mg each) were rapidly rinsed in 0.9% 
saline and submitted to lipolysis investigation. Subject to the volume available, one 
portion of the collected adipose tissue sample was frozen in liquid nitrogen and stored 
at -70
o
C for later gene expression studies. Another portion of the collected adipose 
tissue was used for cytokine secretion, and finally a portion of the collected adipose 
tissue was used for isolation of fat cells and lipogenesis studies. It has previously been 
shown that adipose tissue samples removed and frozen in this way are free from 
damaged cells and blood [88]. It should be pointed out that the adipose tissue samples 
were obtained pre-operatively, by needle biopsy under local anaesthesia and not during 
surgery, as it has previously been demonstrated that general anaesthesia influences 
adipose tissue function [30].   
 
3.2.3 Plasma Analysis 
A venous blood sample was obtained for the determination of haemoglobin, transferrin, 
glucose, triglycerides, high density lipoprotein (HDL), glycerol, free fatty acids, 
albumin, C-Reactive Protein (CRP), insulin-like growth factor I (IGF-I), leptin, 
noradrenalin, adrenaline and insulin by the hospital’s accredited routine chemistry 
laboratories. Additionally atrial natriuretic peptide was measured using a RIA kit 
(Phoenix Peptides). Plasma glycerol and free fatty acid (FFA) levels were presented as 
a ratio of total body fat. TNF-α and IL-6 levels were determined as described by others 
[89].  
 
3.3 LABORATORY STUDIES 
3.3.1 Muscle Biopsy Procedure and Strip Preparation 
Following induction of general anaesthesia, skeletal muscle biopsies (ca 500 mg) were 
surgically excised from the rectus abdominalis muscle. The samples were transported 
immediately to the laboratory in Krebs-Henseleit bicarbonate buffer (KHB) solution 
containing 5mM HEPES, 0.1% bovine serum albumin, 5mM glucose and 15mM 
mannitol. In the laboratory, 10 to 20 muscle strips were prepared from the sample and 
mounted on Plexiglas clamps [90]. For equilibrium, these strips were incubated in KHB 
in sealed vials for 15 minutes.  
 
3.3.2 Glucose Incorporation into Glycogen 
Following the equilibrium period, the skeletal muscle strips were incubated with or 
without insulin (1000mU/mL) for 2 hours in 2 mL of KHB solution containing 5 mM 
glucose and [U-14C] glucose (0.3mCi/mL). After incubation, the muscle strips were 
rapidly removed and frozen in liquid nitrogen at -70
o
C. The frozen skeletal muscle 
strips were processed as described by Cuendet [91], glycogen was precipitated as done 
by Stauffacher [92], and [U-14C] glucose was used to estimate the rate of glucose 
conversion into glycogen. Glucose conversion into glycogen is expressed as nanomoles 
per gram per hour and fold increase over basal glucose conversion into glycogen. 
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3.3.3 ATP, Phosphocreatine, and Glycogen Content 
ATP and phosphocreatine were extracted from 5 mg of ground freeze-dried muscle and 
measured fluorometrically by enzyme methods described by Harris [93]. The glycogen 
content of the muscle was determined using hexokinase and glucose-6-phosphate 
dehydrogenase, measuring the production of reduced nicotinamide adenine 
dinucleotide by spectrophotometry, after alkaline destruction of free glucose and 
hydrolysis of glycogen with amyloglucosidase, described by Lust [94]. The glycogen 
content was expressed as millimoles of glucosyl (a glycosyl radical C16H11O5 derived 
from glucose per kilogram of dry weight [95]).   
 
 
3.3.4 Glucose Transport  
3.3.4.1 Glucose Transport in Isolated Muscle Strips 
The muscle strips were incubated in KHB containing 0 or 1000 mU/mL of insulin for 
30 minutes. Following that [3H] 3-O-methylglucose (5 mM, 2.5mCi/mmol) and [14C] 
mannitol (15 mM, 26.3 mCi/mmol; ICN Biomedical, Costa Mesa, CA, USA) were 
added to the buffers. The vials were subsequently incubated for 20 minutes. All these 
serial incubations were maintained at 35
o
C with 95% O2/5% CO2. 
 Glucose transport was assessed in skeletal muscle using the glucose analogue [3H] 3-
O- methyl glucose, as previously described for rat epitrochlearis muscle [96], with 
modifications for human skeletal muscle as described by Zierath [97]. The 3-O-
methylglucose enters the muscle cells using the same transport carrier protein as 
glucose. This glucose analogue cannot be further metabolized, thus allowing direct 
assessment of glucose transport activity without influencing the glucose metabolism. 
The incubated muscle samples were processed as previously described [96] and sample 
aliquots were counted in a liquid scintillation counter with the channels preset for 
simultaneous measurement of [3H] (glucose) and [14C] (mannitol) . The amount of 
each isotope present in the sample was determined and used to calculate the 
extracellular space (mannitol) and the intracellular concentration of 3-O-methyl 
glucose. The intracellular water content of the muscle sample was determined by 
subtracting the measured extracellular water space from the total muscle water. The 
extracellular space was estimated using [14C] mannitol. Mannitol cannot pass through 
the muscle cell membrane and was therefore used as an indirect measurement of 
muscle cell viability [98]. The basal rate of 3-O-methylglucose transport was expressed 
per millilitre of intracellular water. Insulin-stimulated glucose transport was expressed 
as fold increase over basal.  
 
3.3.4.2 Glucose Transport in L6 Myotubes 
Rat L6 myoblasts, human PDAC-cells (MiaPaca 2) and fibroblasts (HFF1) were 
obtained from the American Type Culture Collection (ATCC; Rockville, MD, USA). 
Human osteosarcoma cells (MG-63) were obtained from a fellow laboratory at the 
Karolinska Institutet. Rat L6 myoblasts were grown in Dulbecco’s Modified Eagle’s 
medium (DMEM) supplemented with 22.5 Mm glucose, 10% (v/v) fetal calf serum 
(FCS), 3% (v/v) 100 U/mL of penicillin, and 3% (v/v) 100 mg/mL of streptomycin 
(PEST). The cells were seeded in 12-well plates. Differentiation of the myoblasts was 
commenced at 80% confluence, by microscope, using DMEM supplemented with 5.6 
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mM glucose, 2% (v/v) FCS, and 3% (v/v) PEST for 5 days with a medium change on 
day 2 and day 4. The differentiation of myoblasts to myotubes was monitored by 
microscopic observation. Starvation was started on day 6, for 21 hours, using either 
DMEM supplemented with 5.6 mM glucose, 0% (v/v) FCS, 3% (v/v) PEST, and 6% 
(v/v) of 1 mg/mL of bovine serum albumin (unconditioned media) or DMEM 
supplemented with 5.6 mM glucose, 0% (v/v) FCS, 3% (v/v) PEST, and 6% (v/v) of 1 
mg/mL of bovine serum albumin conditioned media. Conditioned media was made by 
using DMEM supplemented with 5.6 mM glucose, 0% (v/v) FCS, 3% (v/v) PEST, and 
6% (v/v) of 1 mg/mL of bovine serum albumin, incubated with fibroblasts, osteoblasts, 
or pancreatic carcinoma cells for 24 hours. After those 24 hours in preparation of 
conditioned media, the glucose concentration, was measured and increased up to 5.6 
mM if required. The myotubes were incubated with 0.4 mM 2- deoxyglucose (2-DOG) 
with or without insulin (2000 nM Actrapid) for 60 minutes and thereafter with 
radioactive 2-DOG for 10 minutes. Glucose transport was terminated by ice-cold 
phosphate buffered saline. NaOH was then added for 90 minutes to lyse the cells. 
Protein concentrations were determined by a Bio-Rad colorimetric assay (Bio-Rad, 
Hercules, CA, USA). The radioactivity in the lysate was determined by liquid 
scintillation counting. The 2- DOG uptake was expressed as nanomoles of 2-DOG per 
milligram of protein per minute. MiaPaca 2, HFF1, and MG-63 were grown in media 
according to instructions from the ATCC and the fellow laboratory. The cells had 
undergone 4 to 10 passages from the time they were defrosted, until they were used to 
make the conditioned media. 
 
3.3.5 Isolation of Adipocytes from Adipose Tissue 
The adipocytes were isolated from the adipose tissue according to the collagenase 
procedure described by Rodbell [99]. In summary, the tissue was cut into 20-mg pieces 
and incubated (1 g tissue/mL medium) in Krebs-Ringer phosphate (KRP) buffer (pH 
7.4) containing 4% bovine serum albumin (BSA) and 0.5 mg/mL collagenase Type I 
for 60 minutes at 37
o
C in a shaking water bath. The isolated adipose cells were 
collected on a nylon mesh filter and washed 4 to 5 times with 0.1% KRP-BSA buffer. 
The purity of the isolation procedure was estimated by investigating 200 cells from 
each sample under a light microscope. The number of isolated cells that did not 
resemble adipose tissue cells or cell material that was stuck to an adipose cell was 
always 0 to 2 per 200 counted adipocytes.  
 
3.3.6 Measurement of Adipose Cell Volume and Number 
Mean adipose cell volume and weight was determined in isolated adipose tissue cells as 
follows: The greatest dimension of an adipose tissue cell was determined with direct 
microscopy, and the greatest mean dimension of 100 cells from each patient was 
determined. The mean adipose tissue cell volume and weight was calculated by using 
the formulas developed by Hirsch and Gallian [100]. The coefficient of variation for 
this method is 2% to 3%. The mean value is essentially the same as that determined 
from adipose tissue cell sizing of intact samples of human adipose tissue [100]. The 
total number of adipose tissue cells in the incubated sample was calculated as the lipid 
weight of the incubated adipose tissue cells divided by the mean adipose tissue cell 
weight. The total number of adipose tissue cells in the body was calculated as the 
amount of body fat divided by the mean adipose tissue cell weight. It is well recognized 
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that mean adipose tissue cell volume and weight differs between various adipose tissue 
regions in humans. However, the differences are small and introduce only a marginal 
error when a single source is used for the calculation of total adipose tissue cell 
numbers, as discussed previously [101].  In the whole cohort, total adipose tissue cell 
numbers (mean ± standard error) were 45 ± 4 x 10
9
, which is in the same range as 
found in several other studies [100, 101]. In a separate methodological study, the 
bioimpedance method was used to determine body fat by comparing it with dual-x-ray 
absorbmetry (DEXA) in 7 men and 14 women with a body mass index (BMI) from 17 
kg/m
2
 to 46 kg/m
2
 and age range of 22 to 79 years. There was an excellent correlation 
between the two measures (r = 0.92; linear regression) with slope and intercept near 1.0 
and zero, respectively. The coefficient of variation for the 2 measures was 3.6% in non-
obese patients and 3.9% in obese patients (the group was divided at a BMI of 30 
kg/m2) (not published data). Taken together, these methodological data strongly 
suggest that the determination of the total number of adipose tissue cells in the body is 
accurate. 
 
3.3.7 Lipogenesis 
Lipogenesis assessment in isolated adipose tissue cells was performed as described in 
detail previously [102]. In brief, adipose tissue cells from adipose tissue were isolated 
and incubated for 2 hours at 37
o
C in a buffer containing [3H]-glucose without (basal) 
and with different concentrations of insulin. After incubation, lipids were extracted, and 
glucose radioactive [3H] uptake into the total lipid mass was used as an index of 
lipogenesis. The ability of insulin to stimulate basal lipogenesis was calculated. In 
addition, the half-maximum effective concentration (EC50) of insulin for each 
individual concentration response curve was determined. 
 
3.3.8 Lipolysis 
Isolated adipose tissue cells were prepared by collagenase treatment; adipose tissue cell 
size was determined and lipolysis experiments were performed on isolated adipose 
tissue cells as described [103]. In summary, diluted adipose tissue cell suspensions 
(2%, vol/vol) were incubated in an albumin buffer (pH 7.4) supplemented with glucose, 
ascorbic acid, and, for the insulin experiments, adenosine deaminase and 10
-3
 mol/L of 
8-bromocyclic AMP (8-Br-cAMP). The cells were incubated at 37
o
C for 2 hours 
without (basal) or with increasing concentrations (10
-16–10-5 mol/L, depending on the 
hormone used) of noradrenalin, atrial natriuretic peptide, insulin together with 10
-2
 
mol/L 8-Br-cAMP, 8-Br-cAMP (10
-2
 mol/L) alone, or with 10
-2
 mol/L 8-bromo-cGMP 
(8-Br-cGMP). Thereafter, glycerol release into the incubation medium (lipolysis index) 
was determined. In further lipolysis experiments, the buffer containing 8-Br-cAMP 
plus adenosine deaminase was also supplemented with a maximum effective 
concentration (maximal number receptors) (10
-5
 mol/L) of a highly selective inhibitor 
of hormone-sensitive lipase, 4- isopropyl-3- methyl-2-[1-(3-(S)-methyl-piperidin-1-yl)-
methanoyl]-2H-isoxazol- 5-one, termed BAY [104]. 
The lipolysis data were expressed in two ways.  The first was glycerol release per gram 
of lipids in the studies of mature adipose tissue cells or per gram of protein in the 
preadipocyte studies. The second was as a function of basal (non–hormone stimulated) 
glycerol release. The latter was defined as insulin-induced values divided by 8-Br-
cAMP–induced values in the anti-lipolytic experiments and noradrenaline- or atrial 
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natriuretic peptide induced values divided by basal values in the lipolytic experiments. 
Maximum effect was defined as the value obtained at maximum effective hormone 
concentration. Priority was given to expression of lipolysis as a function of basal rate 
because others have shown a strong correlation between this way of expressing 
lipolysis and HSL gene or protein expression in human subcutaneous adipose cells 
[105].  
 
3.3.9 Preadipocytes 
In five cancer cachexia patients and eight weight-stable control patients, a sufficient 
amount of adipose tissue stroma was obtained for preadipocyte isolation. These cells 
were differentiated exactly as described by Langin [104], for 2 weeks, and lipolysis 
experiments without (basal) or with 10
-5
 mol/L of noradrenaline were performed as 
described by Lofgren [106]. 
 
3.3.10 Gene Expression  
Gene expression analyses were performed as described previously [89]. Total RNA 
was extracted from WAT tissue using the RNeasy mini kit (Qiagen GmbH). The 
Agilent 2100 Bioanalyzer (Agilent Technologies) was used to confirm the integrity of 
the RNA. One microgram of total RNA from each sample was reverse transcribed to 
cDNA using the Omniscript RT kit (Qiagen) and random hexamer primers 
(Invitrogen). cDNA synthesis was performed simultaneously for all patients using the 
same mix of primers and RT kit. In the final volume of 25 µL, 5 ng of cDNA were 
mixed with 2x SYBR green polymerase chain reaction (PCR) master mix (Bio-Rad 
Laboratories, Inc.) and primers (Invitrogen). The primer pairs were selected to yield a 
single amplicon based on dissociation curves and analysis by agarose gel 
electrophoresis.  
The primers used were 5-GTGTCAGACGGCGAGAATG-3 (sense) and 5-
TGGAGGGAGGGAGGGATG-3 (antisense) for adipose triglyceride lipase, 5-
GGAAGTGCTATCGTCTCTGG-3 (sense) and 5-GGCAGTCAGTGGCATCTC-3 
(antisense) for HSL,  
To determine if there were local signs of increased inflammation in adipose tissue, 
subcutaneous WAT was assessed for mRNA expression. Messenger RNA (mRNA) 
was analyzed for IL-6 (NM_000600.2), TNF-α (NM_000594.2), CD68 
(NM_001251.2), and CD3D (NM_000732.4).   
The control used was 5-TGACTCAACACGGGAAACC- 3 (sense) and 5-
TCGCTCCACCAACTAAGAAC-3 (antisense) for 18S.  
Quantitative real-time PCR was performed in an iCycler IQ (Bio-Rad Laboratories 
Inc.) and was quantified using TaqMan kits (Applied Biosystem, Foster City, Calif) for 
Hs00174131_m1 (IL-6), Hs00174128_m1 (TNF-α), Hs00154355_m1 (CD68), and 
Hs00174158_m1 (CD3D). 
Expression of mRNA was normalized to the 18S internal control by using a 
comparative Ct method. The patient with the highest Ct value was used as a reference 
point from which all other Ct values for the target gene and the reference gene was 
subtracted. The Ct values were then normalized to ribosomal RNA for 18S using the 
formula 2ΔCt-target gene / 2ΔCt-reference gene. Previous studies have demonstrated 
that these markers correlate well with infiltration of macrophages (CD68) and T-
lymphocytes (CD3) [107, 108].  
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3.3.11 Protein Expression 
Approximately 300 mg of white adipose tissue was crushed and lysed in a protein 
buffer [1% Triton-X 100, Tris-HCl (pH 7.6), and 150 mmol/L NaCl, 4jC], 
supplemented with protease inhibitors [1 mmol/L phenylmethylsulfonyl fluoride and 
Complete (Boehringer Mannheim)], and homogenized. The homogenate was 
centrifuged and the infranatant was collected and saved. The protein content was 
assayed using BCA Protein Assay Reagent Kit (Pierce). One hundred micrograms of 
total cellular protein was loaded on polyacrylamide gels and separated by standard 12% 
SDS-PAGE. The gels were transferred to polyvinylidine fluoride membranes 
(Amersham Pharmacia).  The blots were blocked for 1 hour at room temperature in 
Tris-buffered saline with 0.1% Tween 20 and 5% non fat dried milk. This was followed 
by an overnight incubation at 4
o
C in the presence of antibodies directed against HSL 
[109] and the control protein β-actin (Sigma). Secondary a-rabbit antibodies conjugated 
to horseradish peroxides were provided by Sigma. Antigen-antibody complexes were 
detected by chemiluminescence using a detection kit (SuperSignal) from Pierce and 
specific bands of complexes were detected and quantified using a Chemidoc XRS 
system and the Quantity One Software from Bio-Rad, and expressed as the HSL/β-
actin ratio. 
 
3.3.12 Cytokine Secretion  
TNF-α and IL-6 secretion in the adipose tissue medium, described above, was 
measured exactly as described previously [89]. In summary, a portion of adipose tissue 
was incubated in an albumin-containing buffer for 2 hours at 37
o
C. After incubation, an 
aliquot of the medium was removed and stored at -70
o
C for later analysis of TNF-α and 
IL-6. The total amount of protein secreted was found to be related to the wet weight, 
lipid weight, and the number of adipose tissue cells in the incubated samples.  
 
 
3.4 RADIOLOGICAL STUDIES  
Computed Tomography (CT) was performed as a staging procedure and assessed by 
the multidisciplinary cancer team. All CT examinations were performed within 1 – 2 
weeks following the diagnosis of cancer or hepatic metastases.  
Later, these images were used to obtain measurements of the total adipose tissue, 
visceral adipose tissue, abdominal and para-spinal muscle areas, using segmentation of 
a 1 cm thick slice through the centre of the third lumbar vertebra. The total WAT area 
was then defined as all pixels with a density within the range of -150 and -40 
Hounsfield units (Hu). The total adipose tissue area that was measured from the CT 
was in cm
2
 and when multiplied by 1 cm (CT segmentation thickness) gave the volume 
in cm
3
. The visceral adipose tissue volume was obtained by a rough manual delineation 
of the abdominal cavity (Fig. 6A). The subcutaneous adipose tissue volume was 
calculated by subtraction of the visceral volume from the total volume. The total 
muscle area was defined as all pixels with a density within the range of 1 to 100 Hu. 
Para-spinal muscle and abdominal muscle were manually delineated (Fig. 6B and 6C) 
carefully avoiding the intestine.  
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Fig. 6. CT image of the abdomen where: (A) the volume of visceral white adipose tissue (WAT); 
(B) the volume of para-spinal muscle; (C) the volume of abdominal muscle, was obtained by a 
rough manual delineation of the abdominal cavity, para-spinal and abdominal muscles. The 
volume is expressed in cm
3
 adipose tissue or muscle. 
 
 
 
 
3.5 STATISTICAL METHODS 
In all the studies the values were reported as: a) mean ± SD / SEM; b) median with 
range. The results were compared using ANOVA and appropriate post hoc tests, 
Student’s unpaired or paired t test, or linear regression by the method of least squares. 
Kruskal-Wallis and Mann-Whitney tests were used to compare SGA and tumour score 
values. Correlation calculations were made according to Pearson.  
In study II, a power calculation was made before patient recruitment and was based on 
the previously known distribution of maximum noradrenalin induced glycerol release 
divided by basal glycerol release [103]. The recruitment of weight-stable patients was 
expected to be easier and anticipated the relative proportion between the three groups 
(CC, WS, GO) to be 2:3:2. Based on these estimations and mean and SD of 
noradrenalin/basal lipolysis, it was calculated that 7 cancer cachexia patients, 11 
weight-stable control patients, and 7 weight-losing control patients had to be recruited 
to detect a 70% difference between cancer cachexia and the two control groups at P < 
0.05 (ANOVA) with 80% power using Sample Power (SPSS, Inc.).  
In study III, the patients were recruited in a consecutive manner as 2 groups; weight-
stable cancer and cancer cachexia. A power calculation was made before patient 
recruitment using Sample Power (SPSS Inc., Chicago, Ill). It was based on the three 
major measures in adipose tissue and in blood circulation in the current study (i.e., gene 
expression, protein secretion, and circulating levels of TNF-α and IL-6). As far as is 
known, there have been no reports on the adipose tissue values in cancer patients, 
except for circulating TNF-α and IL-6 levels, which were determined with other 
methods than those used in our study. Therefore, we used previously published data 
obtained in individuals without cancer for the parameters detailed above [89]. These 
values were generated in our own laboratory using the same methods that we used in 
the current study. Lg-values for means and standard deviations were used to obtain a 
normalized distribution. We conducted a two-group analysis, setting the weight-stable 
group values as the historic mean and standard deviation values and the cancer 
cachexia values as 1.3 times the historic values, thus setting the effect size at 30%.This 
A B C 
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effect size was chosen for two reasons. First, a smaller effect size would necessitate 
recruitment of a very large number of patients. Second, a dietary challenge caused a 
25% to 30% significant change in the measured TNF-α and IL-6 parameters in the 
previous study in individuals without cancer [89]. According to our calculations, it 
would be anticipated that a 30% increase (or decrease) in the cancer cachexia group 
would be found compared to the other groups at a P = 0.05 or better (two-tailed Student 
t test) for mRNA expression, protein secretion, and serum levels of TNF-α and IL-6 if 
we recruited 14 patients in each group with a power ranging from 94% to 99% (mean 
power, 97%). It was initially assumed that the distribution of patients should be equal, 
allocating 14 patients to each group by recruiting 28 patients in a consecutive fashion. 
In fact after recruitment, there were 13 cachectic patients and 15 non cachectic patients 
available for inclusion in the study. However, this had no important effect on the power 
calculation when the power analysis was repeated on the actual number of patients or 
when the two groups were divided into three groups, after histopathological 
examination.  
 
 
3.6 ETHICAL APPROVAL  
The ethics committee for human studies at the Karolinska Institutet approved the study 
protocols and informed consent was obtained from each patient before participation. 
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4 RESULTS 
 
4.1 NUMBERS OF PATIENTS AND THEIR DIAGNOSES  
 
4.1.1 Study I 
There were thirteen patients with PDAC and eight patients in each of the other three 
groups.  There were patients with chronic pancreatitis, patients with cancers other than 
PDAC, and control patients with benign diseases. Table 2 shows the diagnoses of the 
patients in the cancer and benign groups. 
 
Table 2. Diagnoses of patients in the cancer and benign groups in study I. 
Cancer patients Patients with benign disease 
Cholangiocarcinoma 2 
Pancreatic 
cystadenoma 
5 
Gallbladder cancer 2 Benign liver cyst 1 
Papilla of Vater 
cancer 
1 
Idiopathic 
thrombocytopenic 
purpura 
1 
Duodenal cancer 1 
Adenoma of the 
papilla of Vater 
1 
Gastric cancer 1   
Colon cancer 1   
  
4.1.2 Study II 
There were seven cancer patients in the CC group, eleven in the WS group and eight in 
the GO group. Table 3 shows diagnoses of the patients.  
 
Table 3. Diagnoses of patients in study II. 
Cancer Cachexia (CC) Weight-stable cancer (WS) 
Gastro-intestinal obstruction 
in cancer (GO) 
Pancreatic 
Ductal 
Adenocarcinoma 
(PDAC) 
5 
Pancreatic 
Ductal 
Adenocarcinoma 
(PDAC) 
3 
Pancreatic 
Ductal 
Adenocarcinoma 
(PDAC) 
1 
Liver metastasis 
from Colorectal 
cancer 
1 
Liver metastasis 
from Colorectal 
cancer 
4 
Oesophageal 
cancer 
5 
Gastric cancer 1 Gastric cancer 1 
Chronic 
cholecystitis  
1* 
  
Oesophageal 
cancer 
1 
Chronic 
pancreatitis 
1* 
  
Chronic 
pancreatitis 
2*   
* Four patients did not have cancer, two in WS and two in GO groups.    
 34 
4.1.3 Study III 
In the CC group there were thirteen patients, in the WS group there were ten patients 
and in the group with benign disease there were five patients. Table 4 shows the 
diagnoses of the patients in these groups. 
 
Table 4. Diagnoses of patients in study III. 
Cancer Cachexia (CC) Weight Stable (WS) 
Patients with benign 
disease 
Pancreatic 
Ductal 
Adenocarcinoma 
(PDAC) 
6 
Pancreatic 
Ductal 
Adenocarcinoma 
(PDAC) 
7 
Chronic 
cholecystitis  
2 
Liver metastasis 
from Colorectal 
cancer 
1 
Liver metastasis 
from Colorectal 
cancer 
1 
Chronic 
pancreatitis 
3 
Gastric cancer 1 Gastric cancer 1   
Oesophageal 
cancer 
5 
Oesophageal 
cancer 
1   
 
4.1.4 Study IV 
There were thirteen patients in the CC group, seventeen in the WS group and ten in the 
GO group. Table 5 shows the distribution of cancer types in the different groups. 
 
Table 5. Diagnoses of patients in study IV. 
Cancer Cachexia (CC) Weight-stable cancer (WS) 
Gastro-intestinal 
obstruction in cancer 
(GO) 
Pancreatic 
Ductal 
Adenocarcinoma 
(PDAC) 
9 
Pancreatic Ductal 
Adenocarcinoma 
(PDAC) 
4 
Oesophageal 
cancer  
9 
Liver metastasis 
from Colorectal 
cancer 
1 
Liver metastasis 
from Colorectal 
cancer 
5 
Gastric 
cancer 
1 
Gastric cancer 3 Gastric cancer 3   
  Oesophageal cancer 3   
  Cholangiocarcinoma 2   
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4.2 HUMAN CLINICAL STUDIES  
4.2.1 Demographics and Nutritional Status 
Tables 6 - 8 provide lists of the characteristics of the patients in studies I - IV. Patients 
with PDAC in study I were older than patients in the benign control group (Table 6).  
 
Table 6. Characteristics of the patients in study I.  
Measure 
Pancreatic Ductal 
Adenocarcinoma 
(PDAC) 
Cancer 
Chronic 
pancreatitis 
Patients 
with benign 
disease 
p 
BMI, Kg/m2  23,6 ± 1,3 23,0 ± 2 21,3 ± 0,7 25,7 ± 1 N.S. 
Age, years  70 ± 2 68 ± 31 52 ± 3 53 ± 4 < 0,051 
Weight 
loss, % of 
habitual 
weight* 
6 ± 3 3 ± 3 6 ± 3 2 ± 2 N.S. 
NOTE:  Values are mean ± SEM.  
Abbreviations: BMI, Body Mass Index  
*: During previous three months   
1: PDAC vs. benign controls 
 
In studies II and IV patients in the CC group had a lower waist perimeter measurement 
than patients in the WS group, patients in the weight losing groups had lower BMI and 
hip perimeter measurements than the WS group, and there were differences in weight 
loss and PG-SGA between all the groups (Table 7). There were no differences in the 
tumour stage between the groups. 
 
Table 7. Characteristics of the patients in studies II and IV 
Measure 
Cancer 
Cachexia 
(CC) 
Weight-
stable 
cancer (WS) 
Gastro-intestinal 
obstruction in 
cancer (GO) 
p 
BMI, Kg/m2 (n=40) 21,9 ± 0,6 25,1 ± 0,9 20,8 ± 1,3 < 0,011,3 
Age, year (n=40) 64,9 ± 1,9 62,5 ± 2,5 62,7 ± 1,9 N.S. 
Weight loss, % of 
habitual weight (n=36)* 
10,0 ± 1,8 3,1 ± 1,6 17,1 ± 3,2 < 0,0011,2,3 
Waist perimeter, cm 
(n=36) 
85,1 ± 3,3 95,4 ± 2,2 86,8 ± 3,8 < 0,051 
Hip perimeter, cm (n=36) 94,2 ± 1,5 99,5 ± 1,4 92,3 ± 2,4 < 0,051,3 
Waist / Hip ratio (n=36) 0,90 ± 0,09 0,96 ± 0,05 0,94 ± 0,06 N.S. 
PG-SGA, points (n=36) 8 (1-17) 3 (1-13) 12 (3-19) < 0,0011,2,3 
Tumour stage (n=40) 3 (1-4) 3 (1-4) 3 (3-4) N.S. 
NOTE:  Values are mean ± SEM or median (range).  
Abbreviations: N.S. Non Significance; PG-SGA, patient-generated-subjective global assessment; BMI, 
Body Mass Index 
*: During previous six months   
1: Cachexia vs. Weight- stable cancer, 2: Cachexia vs. Cancer with obstruction 
3: Weight-stable cancer vs. Cancer with obstruction 
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In study III patients in the CC group had lost more weight, had lower BMI and higher 
PG-SGA scores than the other groups (Table 8). There were no differences in tumour 
stage between the groups. 
 
Table 8. Characteristics of the patients in study III. 
Measure 
Cancer 
Cachexia 
(CC) 
Weight 
Stable (WS) 
Patients with 
benign disease 
p 
BMI, Kg/m2 (n=28) 22,2 ± 0,6 26,5 ± 1,0 28,0 ± 6,2 < 0,011,2 
Age, year (n=28) 65 ± 2 63 ± 2 59 ± 3 N.S. 
Weight loss, % of 
habitual weight (n=28)* 
11,7 ± 1,8 1,0 ± 1,2 3,0 ± 1,8 < 0,011,2 
PG-SGA, points (n=28) 11 (5-18) 3 (1-3) 4 (1-10) < 0,0011,2 
Tumour stage (n=28) 3 (1-4) 3 (1-4) 0 N.S. 
NOTE:  Values are mean ± SEM or median (range).  
Abbreviations: N.S. Non Significance; PG-SGA, patient-generated-subjective global assessment; BMI, 
Body Mass Index 
*: During previous six months. 1: Cachexia vs. Weight- stable cancer 2: Cachexia vs. No cancer  
 
4.2.2 Energy Expenditure 
There were no differences in the increase in EE from the calculated BMRs between the 
groups, as shown in Table 9. But within the groups, it was only patients in the CC 
group who’s EE had significantly increased from the calculated BMR, results not 
shown. 
 
4.2.3 Body Composition 
Tables 9 and 10 show the patients’ body composition in studies II to IV. In studies II 
and IV patients in the weight losing groups had less adipose tissue mass than patients in 
the WS group.  In other respects there was no statistically significant difference in body 
composition between the groups.  
 
Table 9. Body composition of the patients in studies II and IV. 
Measure 
Cancer 
Cachexia 
(CC) 
Weight-stable 
cancer (WS) 
Gastro-intestinal 
obstruction in 
cancer (GO) 
p 
Body fat, % (n=36) 24,4 ± 1,8 27,4 ± 1,2 22,7 ± 0,4 N.S. 
Fat mass, kg (n=34) 16,5 ± 1,1 21,1 ± 1,0 16,4 ± 2,0 < 0,051,2 
Lean body mass, kg (n=34) 57,7 ± 4,2 58,5 ± 3,5 54,9 ± 4,4 N.S. 
Total body water, kg 
(n=34) 
42,5 ± 2,7 43,0 ± 2,1 43,3 ± 2,6 N.S. 
Increase of EE from BMR, 
% (n=34) 
13,0 ± 2,6  11,2 ± 2,9 14,1 ± 3,7 N.S. 
NOTE:  Values are mean ± SEM.  
Abbreviations: EE, Energy Expedience; BMR, Basal Metabolic Rate 
1: Cachexia vs. Weight- stable cancer; 2: Weight-stable cancer vs. Cancer with obstruction   
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In study III there were differences in the patients´ adipose tissue mass between all the 
groups but no statistically significant differences in lean body mass (Table 10). 
 
Table 10. Shows the body composition of the patients in study III. 
Measure 
Cancer 
Cachexia 
(CC) 
Weight-stable 
cancer (WS) 
Patients with 
benign disease 
p 
Fat mass, kg (n=28) 16,8 ± 1,0 24,0 ± 1,0 31,0 ± 5,4 < 0,0011,2,3 
Lean body mass, kg (n=28) 54,0 ± 3,9 58,4 ± 5,3 49,4 ± 4,8 N.S. 
NOTE:  Values are mean ± SEM.  
1: Cachexia vs. Weight- stable cancer, 2: Cachexia vs. No cancer, 3: Weight-stable vs. No cancer  
 
4.2.4 Plasma Glucose, Insulin Concentrations, OGTT 
Glucose tolerance was normal in all of the control patients, whereas 11 of 13 patients 
with PDAC were diabetic or glucose intolerant. Fasting plasma glucose concentrations 
were significantly increased in patients with PDAC compared with control patients and 
patients with other cancers. Fasting plasma insulin concentrations were not statistically 
different across groups, although insulin levels tended to be increased in patients in the 
cancer and PDAC groups and decreased in patients in the CP group compared with 
control patients. Results are presented in Table 11.  
 
Table 11. Glucose and insulin concentrations and OGTT in study I. 
Measure 
Pancreatic Ductal 
Adenocarcinoma 
(PDAC) 
Cancer 
Chronic 
pancreatitis 
Patients 
with 
benign 
disease 
p 
OGTT (normal 
/ impaired / 
diabetes) 
2 / 3 / 8 5 / 0 / 3 3 / 1 / 4 8 / 0 / 0 < 0,051,2,3 
Fasting plasma 
glucose, mM 
8,1 ± 0,6 5,3 ± 0,3 7,0 ± 1,0 5,0 ± 0,1 < 0,051,2 
Fasting plasma 
insulin, pM 
50 ± 9 59 ± 6 30 ± 8 40 ± 4 N.S. 
FFAs, mM 0,86 ± 0,05 1 ,19 ± 0,08 1,50 ± 0,48 0,72 ± 0,06 N.S. 
NOTE:  Values are mean ± SEM or absolute number.  
Abbreviations: OGTT, Oral glucose tolerance test; FFAs, Free Fatty Acids  
1: PDAC vs. benign controls, 2: PDAC vs. cancer, 3: Chronic pancreatitis vs. Benign controls 
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Fig. 7. Tumour necrosis factor α (B) was similar 
in the three groups but there was an increased 
level of interleukin 6 (A) in the cancer cachexia 
group. Nutrition (2010), doi:10.1016/j.nut. 
2010.08.022. 
4.2.5 Serum Levels of IL-6 and TNF-α 
Circulating levels of IL- 6 were increased in 
the cancer cachexia group (p < 0,05) (Fig. 
7A) compared to the two other groups. 
Circulating levels of TNF-α were similar in 
all three groups (Fig. 7B).   
 
4.2.6 Other Plasma and Serum 
Measurements 
Tables 12 and 13 show various plasma and 
serum measurements in studies II-IV. Table 
12 shows that in studies II and IV, glycerol 
and free fatty acid levels were higher in 
patients in the CC group than in patients in 
the WS group. The weight losing groups had lower levels of triglyceride, cholesterol 
and leptin than patients in the WS group (p < 0.01-0.05).  
 
Table 12. Plasma and serum measurements in studies II and IV. 
Measure 
Cancer 
Cachexia 
(CC) 
Weight-stable 
cancer (WS) 
Gastro-intestinal 
obstruction in 
cancer (GO) 
p 
P-Noradrenaline, nmol/L (n=26) 2,2 ± 0,4 3,0 ± 1,0 2,4 ± 0,2 N.S. 
P-Adrenaline, nmol/L (n=26) 0,22 ± 0,14 0,20 ± 0,13 0,25 ± 0,24 N.S. 
P-Atrial natriuretic peptid, ng/L 
(N=26) 
13 ± 5 12 ± 4 14 ± 4 N.S. 
P-Glucose, mmol/L (n=36) 6,7 ± 0,5 6,2 ± 0,4 5,5 ± 0,2 N.S. 
P-Insulin, mU/L (n=33) 5,3 ± 1,0 10,4 ± 2,0 7,1 ± 1,9 N.S. 
P-Triglyceride, mmol/L (n=36) 0,9 ± 0,1 1,4 ± 0,1 0,9 ± 0,1 < 0,011,2 
P-HDL, mmol/L (n=36) 1,6 ± 0,2 1,5 ± 0,1 1,7 ± 0,2 N.S. 
P-Cholesterol, mmol/L (n=34) 4,2 ± 0,3 5,2 ± 0,3 4,1 ± 0,3 < 0,051,2 
P-Leptin, ng/mL (n=36) 4,5 ± 0,6 9,0 ± 1,5 4,3 ± 0,8 < 0,051,2 
S-IGF-I, µg/L (n=36) 109,8 ± 10,2 111,3 ± 13.8 95,7 ± 15,8 N.S. 
S-Albumin, g/L (n=36) 35,1 ± 1,3 37,2 ± 0,9 34,7 ± 1,2 N.S. 
S-C-Reactive Protein, µg/L (n=36) 26,9 ± 11,6 4,86 ± 2,2 14,1 ± 9,6 N.S. 
P-Glycerol, µmol/L/kg body fat 
(n=33) 
6,9 ± 1,3 3,9 ± 0,6 6,4 ± 0,6 < 0,051 
P-Free Fatty Acids, µmol/L/kg fat 
(n=33) 
53,8 ± 8,6 32,5 ± 3,6 51,9 ± 7,3 < 0,051 
NOTE:  Values are mean ± SEM. Abbreviations: P, Plasma; S, Serum.; N.S., Non Significant; HDL, High 
Density Lipoprotein; IGF-I, Insulin-like Growth Factor I;  
 1: Cachexia vs. Weight- stable cancer; 2: Weight-stable cancer vs. Cancer with obstruction 
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Fig. 8. Glycogen content (A) and glucose incorporation into glycogen in the absence (B) or presence 
(C) of insulin in skeletal muscle, incubated in glucose. Data presented as mean ± SEM.  * P < 0.05 
compared with control. CP, chronic pancreatitis; PC, Pancreatic Ductal Nutrition (2010), 
doi:10.1016/j.nut.2010.08.022. 
 
In study III glycerol and free fatty acid levels were higher and transferrin levels were 
lower in patients in the CC group compared to patients in the other groups (p < 0,05) 
(Table 13). 
 
Table 13. Plasma and serum measurements in study III  
Measure 
Cancer 
Cachexia 
(CC) 
Weight Stable 
(WS) 
Patients with 
benign disease 
p 
P-Glucose, mmol/L (n=28) 6,1 ± 0,4 6,8 ± 0,6 7,3 ± 1,1 N.S. 
P-Insulin, mU/L (n=28) 6,5 ± 0,9 12,8 ± 3,2 16,2 ± 5,2 N.S. 
Haemoglobin, g/L (n=28) 131 ± 5,1 134 ± 5,3 123 ± 5,4 N.S. 
S-Albumin, g/L (n=28) 34,3 ± 1,2 38,0 ± 0,9 38,8 ± 1,8 N.S. 
S-Transferrin,g/L (n=28) 2,1 ± 0,1 2,6 ± 0,1 2,7 ± 0,2 < 0,051,2 
P-Glycerol, µmol/L/kg body fat 
(n=28) 
9,8 ± 2,0 3,3 ± 0,3 3,2 ± 0,4 < 0,051,2 
P-Free Fatty Acids, µmol/L/kg fat 
(n=28) 
87,0 ± 2,0 30,0 ± 0,4 34, 0 ± 1,0 < 0.051,2 
NOTE:  Values are mean ± SEM. Abbreviations. P, Plasma; S, Serum; N.S., Non Significant 
 1: Cachexia vs. Weight- stable cancer; 2: Cachexia vs. no cancer 
 
 
4.3 LABORATORY STUDIES 
4.3.1 Glycogen  
 Glycogen content was significantly lower in patients in the PDAC group than in 
patients in the control group (119 ± 17 
versus 213 ± 24 mmol of glycosyl units/kg 
of dry weight, p < 0.05; Fig. 8A). 
Glycogen content in patients in the CP and 
cancer groups was not different from 
patients in the control group. There were 
no statistically significant differences 
between patients in the PDAC and cancer 
groups. In all patients, glycogen content 
was significantly correlated with ATP 
content (R
2
 = 0.74, p < 0.05). In the basal 
state, glucose incorporation into glycogen 
was not significantly different across 
groups, although patients in the CP, 
cancer, and PDAC groups tended to have 
lower rates (Fig. 8B). Insulin stimulation 
resulted in a 1.3-fold increase of glucose 
incorporation into glycogen (p < 0,05) in 
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Fig. 9. Content of ATP (A) and phosphocreatine (B) 
in skeletal muscle. Data are presented as mean ± 
SEM. * P < 0.05 compared with control. ATP, 
adenosine triphosphate; CP, chronic pancreatitis; 
PC, Pancreatic Ductal Adenocarcinoma. Nutrition 
(2010), doi:10.1016/j.nut.2010.08.022. 
 
Fig. 10. The 3-O-methylglucose transport in 
isolated muscle strips, incubated in glucose in 
the absence (A) or presence (B) of insulin. Data 
are presented as mean ± SEM. * P < 0.05 
compared with control. CP, chronic pancreatitis; 
PC, pancreatic cancer. Nutrition (2010), 
doi:10.1016/j.nut.2010.08.022. 
patients in the control group (Fig. 8C). In patients in the PDAC, CP and cancer groups, 
insulin stimulation did not result in a significant increase in glucose incorporation into 
glycogen.  
 
4.3.2 ATP and Phosphocreatine Content 
The ATP content was significantly lower in 
patients in the PDAC group than in the 
control group (8.4 ± 1.2 versus 15.8 ± 0.8 
mmol/kg of dry weight, P < 0.05). There were 
no statistically significant differences between 
patients in the PDAC and cancer groups. 
Patients in the CP and cancer groups also had 
decreased muscle ATP content, but these did 
not reach statistical significance compared 
with patients in the control group (Fig. 9A). 
The trend was similar for phosphocreatine 
content, although the differences between 
means across the groups were not statistically 
significant (Fig. 9B).  
 
4.3.3 Glucose Transport 
4.3.3.1 Activity in Isolated Muscle Tissue 
Basal 3-O-methylglucose transport was not 
significantly different among patient groups 
(Fig. 10A). Insulin stimulation resulted in a 
significant fold increase in glucose 
transport in all patient groups, except those 
with PDAC (data not shown). Insulin-
stimulated glucose transport was 
significantly decreased in patients with 
PDAC compared with the control group 
patients (Fig. 10B). Insulin-stimulated 
glucose transport in patients in the CP and 
cancer groups was not different from that in 
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Fig. 11. (A) Basal and insulin-stimulated 2-
DOG transport and (B) insulin stimulated fold 
increase over basal, L6 myotubes in 
conditioned media. 2-DOG, 2-deoxyglucose; 
FB, fibroblasts; MP2, MiaPaca 2; OB, 
osteosarcoma cells; UM, unconditioned 
medium. Nutrition (2010), doi:10.1016/ 
j.nut.2010.08.022. 
 
Fig. 12. There was no difference between 
the groups in insulin-stimulated 
lipogenesis. P value given is for the overall 
difference and was determined by 
repeated-measures analysis of variance. 
CANCER 2008; 113(7), 1695-1704. 
 
patients in the control group, although there was a tendency for decreased glucose 
transport in patients in the cancer group. In all patients, there was no correlation 
between insulin-stimulated glucose transport and muscle ATP content (data not 
shown).   
 
4.3.3.2 Activity in L6 Myotubes 
Transport of 2-DOG was determined with and 
without the presence of 2000 nM insulin. Basal 
glucose uptake was similar across the groups 
(Fig. 11A), and exposure to insulin resulted in a 
significant increase in glucose transport in all 
patient groups (Fig. 11B). There were no 
significant differences in basal or insulin 
stimulated glucose transport in myotubes without 
or with exposure to medium conditioned by 
PDAC cells, fibroblasts or osteoblasts.   
 
 
 
 
 
 
 
 
 
 
4.3.4 Lipogenesis 
Figure 12 shows that the concentration 
response curves in the three patient groups 
were superimposed almost completely. The 
maximum insulin effect and EC50 were 
calculated for each patient. The maximum 
insulin effect in the three groups varied 
between 2.3- and 2.6-fold stimulation (p = 
0.51). EC50 for insulin varied between 0.02 
and 0.04 nmol/L in the three groups (p = 
0.92). Therefore, insulin-stimulated 
lipogenesis was almost identical in the three 
studied patient groups. Basal lipogenesis 
(expressed per number of isolated fat cells) 
did not differ between patient groups (p = 
0.35). 
 
 
 
 
 42 
Figure 13. Lipolysis in mature fat cells of cachexia, weight stable and gastro-intestinal obstruction 
patients. ANP, atrial natriuretic peptide. Cancer Res 2007;67(11):5531–7 
4.3.5 Lipolysis 
Insulin inhibited lipolysis in a similar concentration-dependent manner in the three 
patient groups. Maximum inhibition of lipolysis varied from 55% to 60% in these 
groups. Noradrenaline and atrial natriuretic peptide stimulation of basal lipolysis rate 
was much more efficient (P < 0.001, ANOVA repeated measure) in CC patients as 
compared with the control groups, who did not differ between each other. At the 
maximum effective concentration, noradrenaline stimulated lipolysis 5-, 3-, and 2.5-
fold in the CC, WS, and GO patient groups respectively (p = 0.01). Corresponding 
values for natriuretic peptide were 7-, 4-, and 3-fold (p = 0.02) (Fig.13). 
When lipolysis was expressed as absolute values of glycerol release (µmol/g of lipid/2 
h), as shown in Table 13, this mode of expression gave similar results to those above; 
however, some of them did not reach a level of statistical significance (P = 0.06–0.07). 
Furthermore, basal (nonhormonal) lipolysis did not differ between patient groups 
(Table 14).  
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Fig. 14. Lipolytic effect of a cAMP analogue (8-bcAMP) with or without HSL inhibitor BAY. Cancer 
Res 2007;67(11):5531–7 
Fig. 15. Lipolysis in preadipocytes differentiated into adipocytes. Cancer Res 
2007;67(11):5531–7 
 
 
Table 14. Shows lipolysis expressed as absolute values of glycerol release (µmol/g of lipid/2 h) 
Condition 
Cancer 
Cachexia 
(CC) 
Weight-stable 
cancer (WS) 
Gastro-intestinal 
obstruction in 
cancer (GO) 
p 
Basal  0,98 ± 0,7 1,16 ±0,67 1,49 ± 0,67 0,44 
Noradrenaline  3,1 ± 1,7 1,5 ± 1,0 1,49 ± 0,67 0,06 
Atrial natriuretic peptide 4,0 ± 1,5 2,1 ± 1,9 2,6 ± 1,2 0,07 
8-Br-cAMP 5,1 ±2,3 2,7 ± 2,7 3,1 ± 1,6 0.02 
8-Br-cAMP + insulin 1,9 ± 1,0 1,3 ± 0,7 1,9 ± 0,9 0,31 
NOTE:  Values are mean ± SD of glycerol release (µmol/g of lipid/2h). 
 
 
 The cAMP analogue 8-Br-cAMP caused a 7-fold stimulation of lipolysis in the CC 
patient group as compared with a 3-fold 
stimulation in patients in the WS and GO 
groups (Fig. 14). The selective HSL 
inhibitor BAY decreased the lipolytic effect 
of the cAMP analogue by >90%, with no 
differences between the patient groups (Fig. 
14). Finally, 8-BrcGMP stimulated lipolysis 
10 ± 6-fold in patients with cancer cachexia 
and 3.0 ± 1.6-fold and 2.7 ± 0.5-fold, 
respectively, in patients in the two control 
groups (p = 0.03). 
 
 
4.3.6 Preadipocytes 
 
In preadipocytes (Fig. 15) differentiated to 
adipocytes, the lipolytic effect of 
noradrenaline was the same in patients with 
cancer cachexia and in weight-stable control 
patients (≈8-fold stimulation of basal rate). 
Similar results were obtained when 
preadipocyte lipolysis was expressed as a 
function of cellular protein content (values 
not shown). 
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Fig. 17.  There was no difference in mRNA expression for either (A) interleukin6 (IL-6), (B) tumor 
necrosis factor α (TNF-α), (C) macrophage (CD68), or(D) T-lymphocyte (CD3). 18S indicates internal 
control. CANCER 2008; 113( 7), 1695-1704. 
Fig. 16. Expression of mRNA for hormone 
sensitive lipase (HSL) and adipose 
triglyceride lipase (ATGL). Cancer Res 
2007;67(11):5531–7 
4.3.7 Gene Expression 
4.3.7.1 HSL and ATGL 
In adipose tissue of CC patients, HSL 
mRNA expression was >50% higher 
compared with patients in the two control 
groups, which did not differ between each 
other, but there was no difference between 
the three patient groups in adipose 
triglyceride lipase expression (Fig. 16). As 
regards maximum lipolytic effect of 
noradrenaline or atrial natriuretic peptide, 
both hormones showed a strong positive 
correlation with HSL gene expression (r = 
0.58; p = 0.005 for noradrenaline and r = 
0.50; p = 0.02 for atrial natriuretic peptide; 
graphs not shown). No such correlation was 
observed for adipose triglyceride lipase 
mRNA (r ≈ 0.15). 
 
4.3.7.2 Inflammations Markers 
 In contrast to the elevated serum IL-6 levels, expression of IL-6 mRNA in adipose 
tissue did not differ between the patient groups (Fig. 17A) (p = 0.12). If anything, IL-6 
expression tended to be lower in the CC patient group. Similarly, no differences in 
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Fig. 18.  Relationship between HSL 
protein expression (ratio of actin) and 
lipolytic effect of noradrenaline. Cancer 
Res 2007;67(11):5531–7 
TNF-α expression in adipose tissue were observed (Fig. 17B) (p=0.87). To assess 
whether there were signs of increased leukocyte infiltration in adipose tissue, mRNA 
expression for CD68 (a macrophage marker) and CD3 (a T-lymphocyte marker) were 
measured. Similar to the findings with cytokine mRNA, the levels of CD68 (Fig. 17C) 
(p=0.78) and CD3 (Fig. 17D) (p=0.88) did not differ between groups.  
 
4.3.8 Protein Expression 
The number of subjects investigated was too 
small for an analysis of the three separate 
patient groups. However, HSL protein 
expression showed 2-fold increase in patients 
with cancer cachexia as compared with the 
two control groups (0.23 ± 0.57 versus 0.69 ± 
0.34; p = 0.032). When all protein data were 
compiled, there was a strong positive 
correlation between HSL protein expression 
and noradrenaline-stimulated lipolysis (Fig. 
18). As much as 50% of the variation in 
lipolysis (adjusted r
2
) could be explained by 
variations in HSL. Similar correlations were 
obtained with atrial natriuretic peptide (r = 0.67; p = 0.005) or 8-Br-cAMP (r = 0.85; p 
< 0.001). The results were not altered in a significant way when absolute values for 
HSL expression were used instead of HSL/actin ratio (r = 0.67–0.85; graphs not 
shown). h-Actin expression was not correlated with lipolysis (r = 0.03–0.07). The 
mRNA and protein expression of HSL showed a very strong correlation (r = 0.81; 
p=0.001). 
 
4.3.9 Adipocytes Number and Volume 
The adipocytes in patients in the CC group were smaller than the adipocytes in patients 
in the WS or no cancer groups. There were no differences between patients in the CC 
and GO groups (Table 15 and 16). There were no differences in the number of 
adipocytes between the patient groups (Table 16). 
 
Table 15. Adipocyte volume in study II. 
Measure 
Cancer 
Cachexia 
(CC) 
Weight-
stable cancer 
(WS) 
Gastro-intestinal 
obstruction in 
cancer (GO) 
p 
Adipocyte volume, pL (n=26) 299 ± 85 653 ± 176 395 ± 102 < 0,0011 
NOTE:  Values are mean ± SEM. 1: Cachexia vs. Weight- stable cancer 
 
Table 16. Adipocyte volume and number in study IV. 
Measure 
Cancer 
Cachexia 
(CC) 
Weight Stable 
(WS) 
Patients with 
benign disease 
p 
Adipocyte volume, pL (n=26) 339 ± 30 574 ± 40 678 ± 113 < 0,0011,2 
Adipocyte number, x 109 42 ± 2 45 ± 2 49 ± 10 NS 
NOTE:  Values are mean ± SEM. 1: Cachexia vs. Weight- stable cancer; 2: Cachexia vs. No cancer 
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Fig. 19. In adipose tissue, no difference was noted in (A and B) IL-6 secretion or (C and D) TNF-α 
secretion, regardless of whether secretion was expressed per wet weight (ww) (A and C) or per x 10
7
 
fat cells (B and D). CANCER 2008; 113( 7), 1695-1704. 
4.3.10 Cytokine Secretion 
To determine whether the secretion of IL-6 and TNF-α from adipose tissue 
corresponded to the findings at the mRNA level, in vitro incubations of adipose tissue 
specimens were analyzed. The secretion rate of IL-6 did not differ significantly 
between specimens from the three patient groups irrespective of whether the rate was 
expressed per gram of wet weight fat tissue (Fig. 19A) (p =0.65) or per 10
7
 fat cells 
(Fig. 19B) (p =0.36). Similarly, there was no significant difference in TNF-α secretion 
expressed in either of the 2 ways (Fig. 19C,D) (p =0.81 and p = 0.96, respectively). 
There was also no between-group difference when protein secretion was expressed per 
lipid weight of adipose tissue (values not shown). 
 
4.4 CORRELATIONS BETWEEN SELECTED VARIABLES  
In patients in the CC group, percentage weight loss correlated with both glycerol 
(r
2
=0.66, p<0.0005) and circulating fatty acids (r
2
=0.65, p< 0.0005). There was also a 
correlation between the volume of visceral adipose tissue and waist perimeter (r
2
=0.7, 
p< 0.005). In patients in the WS group, waist perimeter correlated with both visceral 
adipose tissue (r
2
=0.85, p<0.001) and fat mass (r
2
=0.62, p<0.0005). In patients in the 
GO group, the volume of visceral adipose tissue correlated to both fat mass (r
2
=0.63, 
p<0.05) and waist perimeter (r
2
=0.65, p<0.01). The amount of visceral adipose tissue 
was negatively correlated to both glycerol (r
2
=0.76, p<0.05) and free fatty acids 
(r
2
=0.79, p<0.01). There was a correlation between the volume of subcutaneous adipose 
tissue with both fat mass (r
2
=0.72, p<0.05) and perimeter of waist (r
2
=0.85, p<0.001). 
There was a negative correlation between the percentage weight loss and fat mass 
(r
2
=0.61, p<0.05).  
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There was a correlation between waist perimeter and volume of visceral adipose tissue 
in patients in all groups (CC (r
2
=0.70, p<0.005), WS (r
2
=0.85, p<0.001), GO (r
2
=0.65, 
p<0.01). Neither CRP nor basal metabolic rate correlated with any other metabolic 
variable. 
 
4.5 RADIOLOGICAL STUDIES 
There was less visceral adipose tissue in patients in the CC group compared to patients 
in the WS group (p < 0.05). In contrast, no statistically significant difference was 
observed in visceral adipose tissue between patients in the GO and WS groups. Both 
weight-losing patient groups had less subcutaneous and visceral adipose tissue (p < 
0.001) compared to patients in the WS group. There were no differences in the volumes 
of vertebral or abdominal muscle across the patient groups (Table 17). 
 
 
Table 17.  Volume of muscle and adipose tissue in cm3 in study IV. 
Measure 
Cancer 
Cachexia 
(CC) 
Weight-
stable cancer 
(WS) 
Gastro-
intestinal 
obstruction in 
cancer (GO) 
p 
Para-vertebral muscle, cm3 (n=40) 72.8 ± 4.6 78.7 ± 4.3 70.4 ± 3.4 N.S. 
Abdominal muscle, cm3 (n=40) 52.1 ± 3.3 60.5 ± 5.3 51.9 ± 4.0 N.S. 
Total adipose tissue, cm3 (n=40) 195.4 ± 3.5 336.4 ± 3.1 196.6 ± 4.0 < 0.011,2 
Subcutaneous adipose tissue, cm3 
(n=40) 
98.8 ± 7.5 159.7 ± 13.1 86.8 ± 21.0 < 0.0011,2 
Visceral adipose tissue, cm3 (n=40) 96.6 ± 20.2 176.6 ± 22.0 109.8 ± 35.1 < 0.051 
NOTE:  Values are mean ± SEM.  
1: Cachexia vs. Weight- stable cancer, 2: Weight-stable cancer vs. Cancer with obstruction  
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5 DISCUSSION 
 
5.1 DEMOGRAPHICS AND NUTRITIONAL STATUS 
Patients with CC (studies II-IV) and PDAC (study I) lost a greater percentage of their 
weight than patients in the WS group, 10% vs. 3%, in study I (6% vs. 2%) (Tables 6, 7 
and 8). These were patients who had no evidence of a mechanical reason for impaired 
food intake and were therefore demonstrating true cancer cachexia [5]. Their PG-SGA 
score was 8 which was higher than for patients in the WS group. Patients in the GO 
group had lost 17% of their habitual weight in the previous 6 months, more than three 
times what would be regarded as normal weight loss over a 6 month period [18].  Their 
PG-SGA score was 12, which was significantly higher than the scores of patients in the 
CC group. PG-SGA score 0-8 means patients are regarded as ―Not at nutritional risk‖ 
where patients who score ≥ 9, are considered to be ―At nutritional risk‖ [110]. Patients 
in the GO group were classified as being moderately to severely malnourished, at the 
time their cancer was diagnosed [110]. BMI and hip perimeter measurements were 
smaller in patients in the weight losing groups compared to patients in the WS group. 
Waist perimeter measurement was smaller in patients in the CC group compared to 
those in the WS group, and was not significantly different between patients in the GO 
group and WS group. There was good and statistically significant correlation between 
waist perimeter and volume of visceral adipose tissue in patients in all the groups. It is 
difficult to discuss the importance of this finding, no-one having noted this in the 
literature before and it is not possible to say if this is related to diminished volume of 
visceral adipose tissue. Tumour staging was similar across all patients groups, which 
indicates that the severity of the cancer disease did not explain the differences observed 
in this study. The self reported information about weight loss is a possible source for 
recall bias, but the bias would be similar for all patient groups and other researchers 
have shown that this is a relatively minor bias [111]. 
 
 
5.2 ENERGY EXPENDITURE 
Table 9 showed that there were no differences between the patient groups regarding 
increased REE from the calculated BMR. But within the groups, patients in the CC 
groups had a significantly increased REE (results not shown). When taking into 
account that all the patients were newly diagnosed with cancer, it could be speculated 
that there would be a difference between the patient groups in the future, when the 
disease advanced [5] and the finding that there is significant increase in REE in patients 
in the CC group supports that. 
 
 
5.3 BODY COMPOSITION AND RADIOLOGICAL STUDIES 
5.3.1 Adipose Tissue 
Body composition showed that there was less adipose tissue mass in patients in the 
weight losing groups compared to those in the WS group but no difference in 
percentage of body fat, lean body mass or total body water (Tables 9 and10). However, 
only one of the patients was extremely lean (lowest BMI was 14.1 kg/m
2
 and the next 
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Fig 20. (A) Body weight loss, in last 6 months,  (B) 
volume of subcutaneous white adipose tissue 
(WAT)
 
 and (C) volume of visceral WAT in the three 
different study groups, cancer cachexia (CC) 
patients, weight-stable cancer patients (WS)  and 
cancer patients with gastrointestinal obstruction 
(GO).  
18.6 kg/m
2
), indicating that patients who were studied may have been in an early cancer 
cachexia phase, when there is predominantly loss of adipose tissue. There was less 
volume of total adipose tissue and subcutaneous adipose tissue in patients in the weight 
losing groups compared to patients in the WS group (Table 17). This result supports 
other reports, showing that wasting of adipose tissue is the predominant cause of weight 
loss in both newly diagnosed cancer patients with cancer cachexia and in early 
starvation [23, 112, 113]. The most 
interesting finding was that patients in 
the CC group lost more visceral 
adipose tissue than patients in the WS 
group (Fig. 20). Ogiwara et al have 
previously shown that terminally ill 
cancer patients with cachexia, who all 
died within 3 months from the time of 
the CT scan, had less visceral adipose 
tissue than healthy non-obese, non-
cancer control patients [114]. 
Freedman has shown that visceral 
adipose tissue increased during and 
after treatment for breast cancer [115]. 
Figure 20 shows that wasting of 
adipose tissue in patients in the CC 
group was more extensive than could 
be expected when comparing volume 
of adipose tissue (Fig. 20 B and C) to 
percentage weight loss (Fig. 20A).This 
thesis has shown that there was less 
volume of visceral adipose tissue in 
patients in the CC group compared to 
patients in the WS cancer group even 
at the time of diagnosis. The patients’ 
visceral adipocytes were smaller but 
had higher metabolic activity than the 
subcutaneous adipocytes [116-119]. 
 
 
 
5.3.2 Muscle Tissue 
There were no differences in the lean body mass, total body water (Tables 9 and 10) or 
in the volume of muscle (Table 17) between the patients. Why there is no difference in 
volume of muscle between patients in the weight losing groups and those in the WS 
group is interesting. A study of cancer patients with weight loss of about 3% of their 
habitual weight showed no increase in mRNA expression and activity of the ubiquitin-
proteasome pathway [120]. Bossola has shown that there is an increase in mRNA 
expression of the ubiquitin-proteasome pathway in cancer patients with weight loss of 
about 5-6% of their habitual weight [121] and many studies of muscle wasting in 
cancer patients who had lost 10% of their habitual weight, show increased mRNA 
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expression and activity of the ubiquitin-proteasome pathway [32, 122]. These findings 
could indicate that increased mRNA expression of the ubiquitin-proteasome pathway 
starts with 5% weight loss and increased activation of the ubiquitin-proteasome 
pathway starts with 10% weight loss. But the results of this thesis do not confirm that 
suggestion. Patients in the CC group had lost 10 % of their habitual weight and patients 
in the GO group had lost 17%, which indicates that there is a more complicated 
relationship between weight loss and activation of the ubiquitin-proteasome pathway. 
In this thesis, we have two methods, body composition and CT, that indicate non 
significant wasting of muscle tissue in patients in the GO group compared to the others 
groups. A possible explanation is that they were compared to patients in a WS group, 
who had lost 3% of their habitual weight and not compared with a population without 
cancer. But as stated earlier, the activation of the ubiquitin-proteasome pathway had not 
started at weight loss of 3% [120]. Another explanation could be the short period that 
the patients had had the cancer disease.      
 
5.4 SYSTEMIC- AND ADIPOSE TISSUE INFLAMMATION 
In healthy individuals, subcutaneous adipose tissue contributes significantly to in vivo 
circulating IL-6 levels in humans [123]. Furthermore, diet-induced reductions in 
circulating IL-6 occur in parallel with reduced adipose tissue secretion of the cytokine 
[89]. Figure 7 showed that there was increased systemic concentration of IL-6 in 
patients in the CC group (p < 0,05) compared to patients in the other groups but no 
difference in concentration of TNF-α, between the patient groups.  There was a trend 
for a higher systemic level of CRP in patients in the CC group but it was not 
statistically significant (Table 12). In adipose tissue, there was no difference between 
the patient groups regarding expression of mRNA for IL-6 or TNF-α (Fig. 17). 
Increased serum concentration of IL-6 in weight losing cancer patients has been 
reported [124] and increasing concentration of IL-6 correlates to the development of 
cancer cachexia in mice [125] but there is some debate on the role of serum 
concentration of TNF-α in weight losing cancer patients [5]. Controversially there is 
considerable evidence that TNF-α has a role in the wasting of adipose tissue [5, 126] 
and it has been suggested that IL-6 alone could not be responsible for the production of 
cancer cachexia [5]. There was no increased mRNA expression for CD68 (a 
macrophage marker) and CD3 (a T-lymphocyte marker) in the adipose tissue of 
patients in the weight losing group compared to patients in the other groups, which 
indicates that there was no increased inflammation in adipose tissue. 
Also there was no increased production of IL-6 and TNF-α from adipose tissue in 
patients in the weight losing group (Fig. 19).  Because IL-6 secretion was not increased 
in adipose tissue from patients in the CC group, despite elevated circulating levels of 
the cytokine, it is apparent that adipose tissue contributes to the circulating IL-6 levels 
only under certain conditions. In cancer cachexia, other sources that were not examined 
in this study (e.g., the liver and pancreas) may play dominant roles in plasma IL-6, a 
hypothesis that is supported by previously reported findings [127, 128].  
These results do not support the theory [75, 76, 78] that increased wasting of adipose 
tissue in newly diagnosed cancer patients is stimulated by inflammation in the adipose 
tissue.  
A limit of these inflammation studies is that the weight losing group had both patients 
with true cancer cachexia and cancer patients with gastrointestinal obstruction who 
were malnourished because of starvation.       
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5.5 PLASMA AND SERUM MEASUREMENTS 
All patients with known diabetes at the time of recruitment were excluded from the 
study but 11 of the 13 PDAC patients had glucose intolerance or diabetes according to 
OGTT, previously unknown to them. Most patients with PDAC were diabetic or 
glucose intolerant without hypo-insulinemia, as has been previously reported [42, 68], 
indicating the presence of peripheral insulin resistance. Others have shown a 
relationship between diabetes or glucose intolerance with hypo-insulinemia and cancer 
[129]. Even there is evidence for a relationship between diabetes and pancreatic cancer, 
it is difficult to find any association between diabetes and cancer in general [130]. 
Fasting plasma glucose levels were higher in PDAC patient groups compared to 
patients with other-sites cancers and benign control patients. This indicates the presence 
of peripheral insulin resistance. 
Patients in the two weight-losing groups had comparable values for triglyceride, 
cholesterol and leptin compared to patients in the WS group. Even if there was no 
difference in IGF-I concentration, there was a strong trend towards a lower 
concentration in patients in the GO group. Patients in the CC group had higher 
concentrations of glycerol and FFA than those in the WS group (Table 12). As noted 
earlier, patients in the GO group had much higher PG-SGA scores than those in the CC 
group and showed a trend towards low IGF-I. Both SGA and IGF-I are markers of 
malnutrition and this indicates the dangerous situation these patients were in [110, 131]. 
They had lost 17% of their habitual weight and it is known that when weight loss is 
approaching 30% it is incompatible with life [2]. When looking at PG-SGA and IGF-I 
in patients in the GO group and the high levels of glycerol and FFA in patients in the 
CC group, the data clearly suggest that the two weight-losing groups, at least in part, 
have different aetiologies underlying their reported weight loss. 
  
5.6 GLYCOGEN, ATP AND PHOSPHOCREATINE CONTENT 
The glycogen content in patients with PDAC was decreased compared with control 
patients (Fig. 8). This is unlikely to be due to only weight loss, because patients with 
CP had a similar weight loss without decreased muscle glycogen content (Fig. 8). 
Therefore, factors other than weight loss may have contributed to the decreased muscle 
glycogen content in PDAC. In contrast to the findings in control patients, there was no 
significant response to insulin in the rate of incorporation of glucose into glycogen in 
patients with PDAC, CP, or cancer, suggesting decreased insulin-stimulated non-
oxidative glucose metabolism in all these patients compared with controls. There is a 
known association between decreased glycogen production and decreased glucose 
transport [132, 133].  
When comparing glycogen content with muscle content of ATP and phosphocreatine 
(Fig. 8 and 9), the means of the different groups show the same reciprocal pattern, 
although only patients with PDAC had significantly lower contents of glycogen and 
ATP compared with control patients, possibly suggesting an association between non 
oxidative glucose metabolism and energy status of the muscle cells. This hypothesis is 
further supported by a significant correlation between glycogen and ATP content when 
analyzing all patients together. In contrast, there was no correlation between muscle 
glucose transport and energy content, suggesting that other mechanisms are likely to 
contribute to the decreased glucose transport seen in patients with PDAC. 
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5.7 GLUCOSE TRANSPORT 
Insulin-stimulated glucose transport was markedly decreased in isolated skeletal muscle 
from patients with PDAC, confirming historical findings [68] and supporting the 
hypothesis that insulin resistance at the skeletal muscle cell level contributes to the high 
frequency of impaired glucose tolerance or diabetes in these patients [43]. Furthermore, 
11 of 13 patients with PDAC were diabetic or glucose intolerant, indicating that this 
metabolic disturbance is strongly associated with PDAC. Peripheral insulin resistance 
and impaired glucose tolerance have been reported in other cancers [134, 135] and have 
been proposed to be a general malignant phenomenon. It has been suggested that this is 
due to induction of mRNA for TNF-α and down regulation of expression of mRNA for 
glucose transporter 4 (GLUT4) [134]. Three patients with cancers of other sites and 
four patients with chronic pancreatitis were diabetic according to their oral glucose 
tolerance test results. In these patients, insulin-stimulated glucose transport was not 
decreased compared with the controls, suggesting that mechanisms other than skeletal 
muscle insulin resistance, may contribute to their hyperglycaemia. Another possibility 
is that the skeletal muscle insulin resistance is caused by defects in intracellular glucose 
metabolism, such as decreased glycogen synthase activity and increased glycogen 
phosphorylase activity [69]. The decrease of insulin-stimulated glucose transport may 
be due to defective signalling steps proximal to glucose transport, such as decreased 
phosphatidylinositol- 3-kinase activity, as has previously been shown [68]. Increased 
lipid use in muscle has been proposed to cause insulin resistance in muscle [136] and 
increased free fatty acid uptake in muscle results in a decrease in phosphatidylinositol-
3-kinase activity and glucose transport [137]. Another theory related to plasma lipid, is 
that wasting of adipose tissue causes increased plasma lipids concentration, which 
stimulates the activation of vascular endothelial growth factor B (VEGF-B) in muscle 
tissue, which causes up regulation of lipid receptors and down regulation of GLUT-4 
receptors in muscle tissue and causes insulin resistances [138]. 
 
5.8 LIPOGENESIS  
Lipogenesis is a process where three fatty acids are connected to glycerol, with ester 
bonding to build triglyceride [139]. Triglyceride is packaged into very low-density 
lipoprotein (VLDL) and secreted by the liver [140]. There is always de novo 
lipogenesis in humans [141, 142]. Figure 12 shows that lipogenesis is not diminished in 
patients in the CC group compared to the other groups (p>0,05);  there is no difference 
in the concentration response curves between the three patient groups. This information 
supports the theory that it is increased expression and activity of HSL that increases 
lipolysis which is the cause of wasting of adipose tissue in cancer cachexia. But the 
observation that lipogenesis does not diminish is not always a positive thing. It is 
suggested that cancer cells can change their cell membrane structure, by activating de 
novo lipogenesis [143], and in that way change the saturation of their membranes. This 
can protect the cancer cells from mediators of the immune system and from cancer 
treatment. Cancer cells can also directly import lipid to their membrane from dietary 
fat, with their own lipoprotein lipase [143, 144]. 
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5.9 LIPOLYSIS 
5.9.1 Stimulation and Inhibition of Lipolysis 
Lipolysis is the breakdown of lipids. It is the hydrolysis of triglycerides into three free 
fatty acids and glycerol, followed by further degradation, into acetyl units [30]. In our 
study, only patients in the CC group had significantly increased in vivo lipolysis 
although there was no evidence of increased sympathetic nervous activity or elevated 
levels of circulating natriuretic peptide (Table 12). As regards the cellular mechanism 
promoting this increase in lipolysis in human cancer cachexia, the antilipolytic effect of 
insulin was not significantly altered in patients in the CC group (Fig. 13), and it is 
unlikely that increased lipolysis in patients in the CC group is secondary to weight loss 
because patients in the GO group had the same adipocyte lipolytic activity as those in 
the WS group (Fig. 13). In contrast, the lipolytic effects of the two major lipolysis-
regulating hormone systems in man (i.e., catecholamines and natriuretic peptides) were 
markedly increased in patients in the CC group as compared with those in the WS or 
GO patient groups (Fig. 13). Furthermore, stimulation of lipolysis with cAMP or 
cGMP analogues also showed increased effect in patients in the CC group (Fig. 14). 
Noradrenaline and natriuretic peptide stimulate adipocyte lipolysis through separate 
signal pathways (mediated by either cAMP or cGMP) that all converge at HSL, an 
enzyme that is also a target for cAMP and cGMP [73, 145]. The similar findings with 
the two cyclic nucleotides indicate that the cellular mechanism for increased lipolysis in 
cancer cachexia is due to enhanced lipolytic signalling of the hormone systems at the 
post-receptor level because of enhanced function of HSL. Indeed, this seems to be the 
case because lipolysis could be inhibited to the same extent in all three patient groups 
using the highly selective HSL inhibitor BAY (Fig 14). The novel lipase adipose 
triglyceride lipase may be important for determining adipose tissue cell lipolysis [30]. 
However in this study, there was no effect of cancer cachexia on adipose triglyceride 
lipase expression, and the expression of this enzyme did not correlate with lipolysis. 
Furthermore, there was <10% residual adipocyte lipolytic activity in all groups when 
HSL -induced lipolysis was inhibited, suggesting no, or a minor, role of adipose 
triglyceride lipase in the altered regulation of lipolysis in cancer cachexia (Fig.14). 
 
5.9.2 Gene and Protein Expression 
There was a 50% increase in mRNA expression of HSL in patients in the CC group and 
a two-fold increase in the amount of protein expression compared to the other patient 
groups (Figs. 16 and 18). This is in line with what others have found in adipose tissue 
[146]. HSL gene and protein expression correlated strongly with the lipolytic effect of 
noradrenaline or natriuretic peptide and could explain the increase in lipolytic effect. 
Furthermore, mRNA HSL and HSL protein levels were strongly interrelated and over-
expression of HSL led to a marked increase in adipocyte lipase activity [30, 31]. 
 
5.10 PREADIPOCYTES 
When adipocytes, which were differentiated from preadipocytes from patients in the 
CC group, were stimulated with catecholamines or natriuretic peptides, there was no 
increased lipolysis observed, opposite to what was seen in the original adipocytes from 
patients in the CC group. This indicates that the increase in the expression of HSL is 
caused by some unknown stimulant or stimulants and is not an epigenetic factor. The 
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Fig. 21. Flowchart which shows that it is lipolysis, not inflammation, increased apoptosis or decreased 
lipogenesis, which is involved in loss of adipose tissue in cancer cachexia. 
influence of this unknown stimulant had been eliminated in the preadipocytes. These 
factors could be produced within adipose tissue or they could be circulating factors 
produced by certain tumours. One such lipolytic mediator, not investigated here, could 
be ZAG [26, 27]. It is quite possible that ZAG-induced lipolysis is increased in human 
cancer cachexia because the protein stimulates lipolysis through the same pathway as 
catecholamines [147, 148]. mRNA expression of ZAG and adipose tissue secretion of 
ZAG are increased in cancer cachexia, however the concentration of circulating ZAG is 
not increased in cancer cachexia [113]. 
 
5.11 ADIPOCYTES NUMBER AND VOLUME  
Patients in the weight losing groups had significantly smaller adipocytes. Others have 
shown the same results, in cancer-bearing mice [29]. It has also been demonstrated in 
cancer cachexia patients with wasting of adipose tissue, that the small adipocytes are 
companied with adipose tissue atrophy and accompanied by an increase in tissue matrix 
fibrosis [29, 113]. This depletion of adipocytes volume is also an indicator of over 
expression and increased activity in HSL, the adipocytes cannot accumulate 
triglycerides [30, 31] and lose their volume. The same numbers of adipocytes in all 
three groups makes inflammation-stimulated apoptosis [79] an unlikely explanation for 
wasting of adipose tissue in cancer cachexia.   
 
5.12 SUMMARY OF ADIPOSE TISSUE CHANGES IN CANCER CACHEXIA 
In this thesis it has been shown that in 
cancer cachexia, there is increased mRNA 
expression and activation of HSL, in 
adipose tissue. This is the rate limiting 
factor in mobilising free fatty acids from 
lipid (lipolysis). There are no signs of 
increased lipogenesis or apoptosis and no 
signs of increased inflammation, which can 
also reduce lipogenesis, increase lipolysis 
and increase induced apoptosis (Fig. 21).  
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Fig. 22. Flowchart showing classification of cachexia and precachexia according to Bozetti et al. 
JPEN (2009);33(4),361-7.  
5.13 DEFINITION OF CACHEXIA  
Many definitions exist for cachexia and cancer cachexia. 
  
Bozzetti et al divided cancer cachexia into four classes [149] (Fig. 22). The authors 
used the database from an ongoing multicentre prospective investigation on the 
screening of the nutrition risk in 1307 cancer out-patients from different university 
hospitals. The patients were divided into four classes based on combinations of body 
weight loss (<10%, pre-cachexia; ≥10%, cachexia) and the presence/absence of at least 
one another symptom of anorexia, fatigue, or early satiation. This was a combination of 
patients who were either newly diagnosed, waiting for therapy or palliative patients. 
There were no differences made between primary cancer cachexia and weight loss 
which was related to, or caused by, mechanical compression or obstruction by the 
cancer or by the treatment of the cancer such as chemotherapy, radiotherapy or surgery 
[5]. 
 
Fearon et al [150] published a three factor profile: 
 
1. Weight loss (≥10%) 
2. Low food intake (≤1500 kcal/d) 
3. Systemic inflammation (C-reactive protein ≥ 10 mg/L)  
 
They wanted to evaluate whether this might relate better to the adverse functional 
aspects of cancer cachexia and to a patient's overall prognosis than weight loss alone. 
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Their conclusion was that the three-factor profile gave a better prognostic value. This 
was based on 170 palliative pancreatic cancer patients, with median survival 130 days.  
 
In our study many patients in the CC group had normal food intake and median PG-
SGA score 8 (1-17). Score ≤ 8 is defined as ―Not at nutritional risk‖ [110]. Five of 11 
patients in CC group had CRP < 10 mg/L and CRP can also be high in starvation [149]. 
Seven of 13 patients in the CC group had weight loss less than 10% and would 
therefore not be classified as having cancer cachexia.  
 
In many definitions there is a common focus on the loss of skeletal muscle mass [17] 
and the wasting of adipose tissue is not regarded as being essential in cancer cachexia 
[14, 17]. 
 
Even in the two latest definitions, one of which from Blum: 
 
“Cachexia is a multi-factorial syndrome defined by an ongoing 
loss of skeletal muscle mass (with or without loss of fat mass) that 
cannot be fully reversed by conventional nutritional support and 
leads to progressive functional impairment. The pathophysiology 
is characterized by a negative protein and energy balance driven 
by a variable combination of reduced food intake and abnormal 
metabolism”[14] 
 
The other from Fearon et al [151], loss of adipose tissue is not included as one of the 
foundations of cancer cachexia even if many have published its importance before [23, 
112]. One explanation could be that many cancer patients are obese and have 
sarcopenia. When these patients get advanced cancer cachexia, they have enormous 
volumes of adipose tissue and muscle wasting has started [152, 153].     
 
It seems, that all the definitions of cancer cachexia today are focused on patients who 
have very advanced cancer and are in need of, or soon going to need, palliative 
treatment in their home or in a palliative care institute. 
 
According to these classifications of cancer cachexia, about 50% of the patients in the 
CC group would not been included as having cancer cachexia but all have it according 
to Fearon’s latest definitions [151].   
 
It is my belief that I have shown with this thesis that patients in CC group had cancer 
cachexia. 
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6 CONCLUSIONS  
 
To investigate if in pancreatic cancer: 
a) Decreased insulin action on skeletal muscle glucose transport is influenced by 
decreased ATP levels in muscle cells 
b) Pancreatic cancer cells change glucose metabolism in muscle  
 
The in vitro resistance for insulin stimulated glucose transport in the skeletal muscle of 
pancreatic cancer patients is not directly related to factors from pancreatic cancer, 
weight loss, decreased ATP concentration or plasma FFA levels.      
 
To investigate if in cancer cachexia patients: 
a) Inflammation in adipose tissue is increased 
b) Apoptosis in adipose tissue is increased 
c) Lipogenesis in adipose tissue is decreased 
     
It is lipolysis, not inflammation, increased apoptosis or decreased lipogenesis, which is 
involved in loss of adipose tissue in cancer cachexia. 
 
To investigate in cancer cachexia patients: 
a) The rate of lipolysis  
b) The factors involved in lipolysis  
 
There is increased expression and activity of Hormone Sensitive Lipase (HSL), which 
leads to an increased rate of lipolysis in patients with Cancer Cachexia. 
 
To investigate if in cancer cachexia patients: 
a) There is a difference in the volume of adipose- and muscle compartments 
between cancer cachexia patients and benign disease control patients 
b) Adipose tissue wasting is an early phenomenon in the cancer cachexia 
syndrome 
 
Although cancer patients with gastrointestinal obstruction, at the time of diagnosis have 
lost almost twice the amount of their habitual body weight compared to patients with 
cancer cachexia, the latter group displays more loss of visceral adipose tissue. Wasting 
of adipose tissue is a prominent part of cancer cachexia syndrome and starts before the 
wasting of muscle tissue. 
 
 
There is a need for a more specific definition for cancer cachexia in newly diagnosed 
cancer patients.  
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7 POPULÄRVETENSKAP 
 
Introduktion: Ordet kakexi, kommer från orden kakos och hexis och härstammar från 
det grekiska språket och är en beskrivning av ett dåligt tillstånd. 
 
Tanken att ett tumörämne kan ge upphov till cancer kakexi publicerades för första 
gången 1962. Innan dess trodde man att kroppen förstör fett och muskelvävnad för att 
"mata" tumören. 
   
Kakexi är ett kliniskt syndrom som är svårt att definiera. De flesta relaterar det till 
viktminskning hos cancerpatienter. Avancerad kakexi präglas av kraftig viktminskning, 
anorexi, tidig mättnadskänsla, svaghet, anemi och ödem. I början av kakexi kan dessa 
drag förekomma i varierande grad men symptomen kan förändras i svårighetsgrad 
under sjukdomsgången. Den komplexa, mångfasetterade ursprungliga kakexin, följer 
inte någon enhetlig patofysiologisk profil och detta har skapat hinder för att behandla 
kakexi. Cancer kakexi syndromet är vanligt hos patienter med mag-, tarmcancer. Hos 
dessa patienter är cancer kakexi en synonym för alla tecken och symtom de kan 
utveckla, som inte har anknytning till eller orsakas av mekanisk kompression eller 
obstruktion av cancer eller av behandling av cancer, såsom kemoterapi, strålbehandling 
eller kirurgi. Även med intensivt nutritionsstöd, är det svårt att vända processen. Förlust 
av andningsmuskulatur hos cancerpatienter med kakexi har visat sig bidra till upp till 
50 % av dödsfallen hos cancerpatienter. Viktminskning närmare 30 % är inte förenligt 
med liv. 
 
Syfte: Vårt mål var att undersöka effekten av insulin på glukosmetabolismen och 
innehåll av energimetaboliter i muskeln hos patient med pankreascancer (PC) och om 
förändringar i nedbrytning av fett, antal fettceller, produktion av fett eller cytokiner 
koncentration och/eller infiltration av vita blodkroppar in i fett, kunde redogöra för 
några av de funktionella förändringar som observerats i fettväv i cancer kakexi (CK). 
Målet var också att se om volym som fastställs genom datortomografi (DT) kan ge 
information om distribution och mängd av muskler, subkutan och abdominal fettväv 
hos patienter som nyligen fått diagnosen cancer kakexi. 
 
Material och metoder: Venösa blodprov togs på patienten, glukosbelastning utfördes, 
fettvävnadsbiopsier erhölls under lokalbedövning, energiförbrukning och mätning av 
kroppssammansättning gjordes vid patientens kliniska laboratorium. För PC group och 
tre kontroll grupper, var muskelbiopsier tagna i operationssalen och frystes omedelbart 
eller transporterades färsk direkt till laboratorium och analyserades för glykogen, 
adenosintrifosfat och phosphocreatine innehåll. Glukostransport kontrollerades i 
mänskliga muskeltrådar och muskelceller från råtta. För patienter med CK och två 
cancer kontroll grupper, vikt stabila (VS) och med stopp i mag- tarmkanalen (SM), alla 
med nydiagnostiserad sjukdom, var fettvävnadsbiopsier transporterades färska till 
forskningslaboratorium för mätning av 1) nedbrytning av fett, samt mätning av ämnet 
som styr nedbrytning av fett, hormonkänslig lipas (HSL) och HSL genuttryck, 2) 
genuttryck för inflammation markörer och mätning av inflammation i blodet och 
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cytokiners sekretion i fettväv, 3) volym och nummer av fett celler. Slutligen var 
muskel- och fettvolym mätt med DT. 
 
Resultat: Patienter med CK har förlorad10% av sin vanliga vikt, VS gruppen 3% och 
SM gruppen 17%. Insulinstimulerad glukostransport, muskelglykogen och 
adenosintrifosfat innehåll var sänkt hos patienter med PC jämfört med kontrollgruppen, 
och insulinstimulans gav inte signifikant ökning i produktion av glykogen in vitro hos 
patienter med PC. Media konditioneras med PC celler påverkade inte glukos transport i 
rått celler. Cirkulerande nivåer av citokin och naturlig nedbrytning av fett var ökade i 
CK-gruppen jämfört med kontrollerna. I CK gruppen visade resultatet mer stimulation 
av fettnedbrytning jämfört med i kontrollgruppen, mängd av HSL protein och gen 
ökade jämfört med kontrollgruppen. Det fanns inga skillnader i mRNA uttryck av 
cytokiner eller sekret i fettvävnad och produktion av fett. Fettcellerna minskade i 
storlek, men deras antal var normala i CK gruppen jämfört med VS gruppen. 
Fettvävnad minskade i CK och SM grupperna. Både enligt DT och i mätning av 
kroppssammansättning visade CK gruppen en selektiv minskning av abdominell 
fettvävnad. 
 
Slutsats: Fettvävnadsförlust är en framträdande del av cancer kakexi syndromet och 
startar före muskelförtvining. Insulinmotstånd för aktiv transport glukos i 
skelettmuskulaturen hos patienter med pankreascancer är inte direkt kopplade till 
faktor/faktorer från bukspottkörtelcancer eller viktminskning. Det är en ökad 
nedbrytning av fett, inte inflammation samt ökad apoptos eller minskad lipogenes, som 
är involverad i förlust av fettvävnad i cancer kakexi. Det finns ett ökat uttryck och 
aktivitet av hormonkänslig lipas (HSL), som ger ökad hastighet av nedbrytning av fett 
hos patienter med cancer kakexi. Även om cancerpatienter med gastrointestinal 
obstruktion, vid tidpunkten för diagnos, nästan har förlorat dubbelt så mycket 
kroppsvikt jämfört med patienter med cancer kakexi, så har den senare gruppen förlorat 
mer av abdominell fettvävnad.      
   63 
8 ÚTDRÁTTUR  
 
Inngangur: Orðið kakexía kemur frá grísku orðunum kako og hexis, og þýðir slæmt 
ástand eða að vera þróttlítill. 
 
Sú hugmynd að æxli gefi frá sér efnið sem getur valdið krabbameins kakexíu, kom fyrst 
fram í grein sem birtist árið 1962. Áður var talið að líkaminn brenndi fitu og vöðvavef, 
í því skyni að "fæða" æxlið. 
   
Kakexía er heilkenni sem er erfitt að skilgreina. Flestir þekkja það sem megrun 
krabbameinssjúklinga. Langt gengin kakexía einkennist af alvarlegu þyngdartapi, 
lystarleysi, slappleika, blóðleysi og bjúg. Krabbameinskakexía er algeng hjá sjúklingum 
með krabbamein í meltingafærum og er samheiti yfir öll þau einkenni sem ekki eru 
tengd stærð æxlisins eða krabbameinsmeðferðinni þ.e. lyfjameðferð, geislameðferð eða 
skurðaðgerð. Þó að þessir sjúklingar fái mikla næringu, þá tekst ekki að snúa ferlinu 
við. Rýrnun öndunarvöðva hjá sjúklingum með kakexíu, stuðlar að allt að 50% 
dauðsfalla þessara sjúklinga. Þegar þyngdartap er yfir 30%, af þyngd fyrir veikindi, þá 
á sjúklingurinn sjaldan langt eftir ólifað. 
 
Markmið: Markmið okkar var í fyrsta lagi að rannsaka áhrif insúlíns á efnaskipti 
sykurs og myndun orku í vöðvum sjúklinga með briskrabbamein (BK). Í öðru lagi að 
kanna hvort að breytingar á niðurbroti eða myndun fitu, fjöldi fitufrumna eða myndun 
bólguefna og/eða flutningur hvítra blóðkorna inn í fituvef, gæti skýrt út þær breytingar 
sem verða í fituvef hjá sjúklingum með kakexíu. Að lokum var athugað hvort magn fitu 
og vöðvavefs, mælt með tölvusneiðmynd, getur gefið upplýsingar um dreifingu og/eða 
rýrnun vöðva og fituvefs hjá sjúklingum sem nýlega hafa greinst með kakexíu. 
 
Efni og aðferðir:  
Vöðvasýni voru tekin úr sjúklingum með briskrabbamein og þremur 
samanburðarhópum og magn glykogens, adenósíns þrífosfats og fosfokreatíns var 
mælt. Sykurflutningar voru rannsakaðir í vöðvum manna og í vöðvafrumum rotta. 
Bláæðablóðsýni og fituvefjapróf úr sjúklingum með krabbameinskakexíu (KK) og 
tveimur samanburðarhópum, öðrum með stöðuga þyngd (ÞS)  og hinum með stíflu í 
meltingarvegi (SM), voru rannsökuð með það að markmiði að 1) einangra fitufrumur og 
reikna út fjölda og stærð;  2) mæla niðurbrot fitu og efnið sem stýrir því, hormón-
næmur lípasa (HSL) 3) mæla framleiðslu á fitu, prótein og genatjáningu og seytun 
bólguefna i fituvef. 
Einnig var orkunotkun og samsetning líkamans mæld og fitu- og vöðvamagn var mælt 
með tölvusneiðmynd.  
 
Niðurstöður: Sjúklingar í KK hópnum höfðu lést um 10% af þyngd sinni fyrir 
veikindi, SM hópurinn 17% og ÞS hópurinn 3%. Það var minna af insúlínörvuðum 
sykurflutningi, vöðva glycogen og adenósíns þrífosfat innihaldi, hjá sjúklingum með 
BK en hjá samanburðarhópunum. Insúlín örvaði ekki framleiðslu á glycogen hjá 
sjúklingum með BK. BK hefur ekki áhrif á flutning sykurs i vöðvafrumum. Magn 
bólguefna í blóði og náttúrulegt niðurbrot fitu var meira i KK hópnum miðað við ÞS og 
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SM hópana. Í KK hópnum var meiri örvun á niðurbroti fitu miðað við ÞS og SM 
hópana, meiri tjáning af HSL mRNA og próteinum. Það var enginn munur milli 
hópanna á framleiðslu á fitu, á tjáningu mRNA bólguefna eða seytingu þeirra í fituvef. 
Fitufrumur minnkuðu í stærð, en fjöldi fitufrumna var sá sami í KK miðað við ÞS og 
SM hópana. Magn fituvefs var minna í KK og SM hópum, bæði þegar fita var 
rannsökuð með tölvusneiðmynd och mælingum á samsetningu líkamans. 
Tölvusneiðmynd sýndi sértæka minnkun á fituvef inni í kviðarholi hjá KK hópnum 
miðað við ÞS hópinn. Enginn munur var á magni vöðvavefs á milli hópanna.   
 
Ályktun: Eyðing fituvefs er áberandi í krabbameinskakexíu heilkenni og byrjar fyrr en 
eyðing vöðvavefs. Það er aukið viðnám fyrir insúlínörvun á virkum sykurflutningi í 
vöðvum sjúklinga með briskrabbamein og það er ekki tengt efni/efnum sem koma 
þaðan eða þyngdartapi. Það er aukið niðurbroti fitu, en ekki bólga í fituvef, aukið 
sjálfsmorð fitufrumna eða minnkuð myndun fitu, sem er orsök fitueyðingar hjá 
sjúklingum með krabbameinskakexíu. Það er aukin tjáning og virkni hormóna-næma 
lípasa (HSL), sem veldur þessu. Þótt krabbameinssjúklingar með stíflu í meltingarvegi, 
hafi við sjúkdómsgreiningu, tapað nær tvöfalt meiri líkamsþyngd borið saman við 
sjúklinga með krabbameins kakexíu, þá hefur seinni hópurinn minna af fitu inni í 
kviðarholinu. 
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